etoposide has been researched along with Neuroblastoma in 297 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (2.69) | 18.7374 |
| 1990's | 76 (25.59) | 18.2507 |
| 2000's | 106 (35.69) | 29.6817 |
| 2010's | 92 (30.98) | 24.3611 |
| 2020's | 15 (5.05) | 2.80 |
| Authors | Studies |
|---|---|
| Alipour, E; Ardestani, SK; Atash, AF; Emami, S; Foroumadi, A; Jafari-Zavareh, M; Khoshneviszadeh, M; Nakhjiri, M; Safavi, M; Shafiee, A | 1 |
| Anderson, E; Ekins, S; Foil, DH; Havener, TM; Hickey, AJ; Makarov, V; Monakhova, N; Puhl, AC; Rank, L; Riabova, O; Zorn, KM | 1 |
| Cheung, NV; Davenport, JW; Felix, CA; Gregory, BD; Li, MM; Rappaport, EF; Slater, DJ; Yu, X | 1 |
| Hamada, M; Ichikawa, D; Imaya, M; Kawashima, N; Kojima, S; Miwata, S; Muramatsu, H; Narita, A; Narita, K; Nishikawa, E; Nishio, N; Takahashi, Y; Wakamatsu, M; Yamamori, A; Yoshida, T | 1 |
| Bartenhagen, C; Berding, M; Chiu, B; Fischer, M; Fischer-Mertens, J; Hellmann, AM; Kahlert, Y; Otte, F; Roderwieser, A; Rosswog, C; Werr, L | 1 |
| Hu, H; Huang, D; Li, F; Li, J; Li, R; Liu, Z; Zhang, W | 1 |
| Burgos-Panadero, R; Navarro, S; Noguera, I; Noguera, R; Sánchez-Sánchez, M; Stoks, M; Vieco-Martí, I | 1 |
| Alfei, S; Brullo, C; Domenicotti, C; Marengo, B; Milanese, M; Valenti, GE; Zuccari, G | 1 |
| Asgharzadeh, S; Asuelime, GE; Chen, SY; Choi, SY; Chronopoulos, A; Kim, ES; Lascano, D; Lee, WG; Marachelian, A; Park, J; Sheard, MA; Zamora, A; Zobel, MJ | 1 |
| Abdrakhmanov, A; Gogvadze, V; Maximchik, P; Senichkin, V; Valter, K; Zhivotovsky, B | 1 |
| Chiu, B; Coburn, J; Harrington, K; Ikegaki, N; Kaplan, DL; Shimada, H; Taylor, JS; Wood, L; Yavuz, B; Zeki, J | 1 |
| Arakawa, Y; Hiwatari, M; Hogetsu, K; Kato, S; Koh, K; Kubota, Y; Takita, J; Watanabe, K | 1 |
| Abassi, Y; Bonne Køhler, J; Capasso, M; Cinatl, J; Jemaà, M; Lasorsa, VA; Massoumi, R; Michaelis, M; Sime, W | 1 |
| Cimetta, E; Esposito, MR; Frasson, C; Fusco, P; Mattiuzzo, E; Tonini, GP; Viola, G | 1 |
| Kapoor, R; Rastogi, N; Sarma, S; Thakkar, D; Wadhwa, T; Yadav, SP | 1 |
| Chen, H; Sheng, W; Xia, H; Zhang, H | 1 |
| Cho, EJ; Cho, HW; Koo, HH; Lee, JW; Lee, S; Lee, SK; Lim, DH; Ma, Y; Sung, KW; Yoo, KH | 1 |
| Ausserlechner, MJ; Hermann, M; Kiechl-Kohlendorfer, U; Obexer, P; Salcher, S | 1 |
| Borriello, L; Cherryholmes, G; DeClerck, YA; Lee, H; Li, W; Lifshitz, V; Makovski-Silverstein, A; Priceman, SJ; Yu, H | 1 |
| Belogurova, M; Berthold, F; Ernst, A; Hömberg, M; Mazanek, P; Proleskovskaya, I; Sterba, J | 1 |
| Ashizuka, S; Baba, Y; Harada, A; Hiramatsu, T; Kaji, S; Kanamori, D; Miyaguni, K; Ohki, T; Sugihara, T; Uchida, G; Yoshizawa, J | 1 |
| Dandoy, CE; Davies, SM; Jodele, S; Lane, A; Myers, K; Teusink-Cross, A; Wallace, G; Weiss, B | 1 |
| Fukushima, T; Hara, J; Hishiki, T; Ikeda, H; Kamijo, T; Kaneko, M; Kaneko, T; Kuroda, T; Matsumoto, K; Nakagawara, A; Nakazawa, A; Ohira, M; Shichino, H; Soejima, T; Tajiri, T; Takahashi, H; Takimoto, T; Teramukai, S; Yokota, I; Yoneda, A | 1 |
| Brandetti, E; Cifaldi, L; Ognibene, M; Pezzolo, A; Pistoia, V; Veneziani, I | 1 |
| Dong, Y; Hua, Z; Jiang, M; Li, Z; Liu, Z; Tan, F; Thiele, CJ; Zhan, Y; Zhang, S | 1 |
| Chiu, B; Coburn, JM; Ikegaki, N; Kaplan, DL; Levitin, D; Yavuz, B; Zeki, J | 1 |
| Aplenc, R; Bagatell, R; Desai, AV; Fisher, B; Getz, K; Huang, V; Li, Y; Seif, AE | 1 |
| Domenicotti, C; Foggetti, G; Fronza, G; Garbarino, O; Izzotti, A; Marengo, B; Menichini, P; Miele, M; Monti, P; Ottaggio, L; Pulliero, A; Speciale, A; Traverso, N | 1 |
| Baker, KS; Carpenter, PA; El-Haddad, A; Elzembely, MM; Park, JR; Pinto, N; Riad, KF; Sayed, HA | 1 |
| Boddy, AV; Duong, JK; Errington, J; Ladenstein, R; Nath, CE; Shaw, PJ; Veal, GJ | 1 |
| Czaplinski, S; Fulda, S; Habermann, K; Hugle, M; Vogler, M | 1 |
| Adkins, ES; Cohn, SL; London, WB; Maris, JM; Mattei, P; Matthay, KK; Meany, HJ; Naranjo, A; Park, JR; Schmidt, ML; Shimada, H; Tenney, SC; Twist, CJ | 1 |
| Berbegall, AP; Blanquer-Maceíras, MT; Ferrández, A; Machado, I; Martinez-Ciarpaglini, C; Navarro, S; Nieto, G; Noguera, R; Yoshida, A | 1 |
| Chen, Z; Fan, Y; Guo, K; Li, H; Lu, J; Nuchtern, JG; Vasudevan, SA; Woodfield, SE; Yang, J; Yu, Y; Zhao, Y | 1 |
| Anvari, S; Daves, M; Foster, JH; Miller, J; Musick, MA; Porea, TJ; Rider, NL; Shah, MD; Wright, TE | 1 |
| Gawdi, A; Mubarak, M; Singal, AK | 1 |
| Dauphin, G; de Araujo, PC; Demarche, M; Forget, P; Leroy, P; Rausin, L | 1 |
| Canepa, E; Colla, R; De Ciucis, CG; Domenicotti, C; Furfaro, AL; Marengo, B; Marinari, UM; Pronzato, MA; Ricciarelli, R; Traverso, N | 1 |
| Ara, T; Buettner, R; DeClerck, YA; Groshen, SG; Ji, L; Jove, R; Nakata, R; Seeger, RC; Sheard, MA; Shimada, H; Yu, H | 1 |
| Cheng, J; Fan, Y; Jia, W; Kim, ES; Liang, L; Lu, F; Nuchtern, JG; Patel, RH; Vasudevan, SA; Xu, X; Yang, J; Zhang, H; Zhao, Y | 1 |
| Beiske, K; Brock, P; Casale, F; Castel, V; Cullinane, C; Erminio, G; Gambini, C; Garaventa, A; Haupt, R; Holmes, K; Kohler, JA; Marquez, C; Munzer, C; Navarro, S; Parodi, S; Peuchmaur, M; Rubie, H; Valteau-Couanet, D | 1 |
| Buck, SA; Caldwell, JT; Edwards, H; Ge, Y; Qing, WY; Taub, JW; Wang, G; Wang, Z | 1 |
| Ahmed, M; Fang, WH; Kumar, P; Kumar, S; Li, HM; Wang, Q | 1 |
| Brock, P; Burchill, SA; Corrias, MV; Dallorso, S; Gregory, WM; Ladenstein, R; Laureys, G; Luksch, R; Papadakis, V; Pearson, AD; Swerts, K; Tchirkov, A; Valteau-Couanet, D; Vicha, A; Viprey, VF | 1 |
| Bai, S; Fan, J; Hou, W; Tian, X; Tong, H; Xu, H | 1 |
| Behfar, M; Beiki, D; Eftekhari, M; Fallahi, B; Fard-Esfahani, A; Ghavamzadeh, A; Hamidieh, AA; Hosseini, AS; Paragomi, P; Shamshiri, A | 1 |
| Bailly, C; Bal-Mahieu, C; Boulet, E; Guilbaud, N; Kruczynski, A; Lansiaux, A; Lartigau, E; Leblond, P; Meignan, S; Pillon, A; Sarrazin, T | 1 |
| Allen-Rhoades, W; Kim, E; Krance, R; Louis, CU; Mazloom, A; Nuchtern, J; Paulino, AC; Russell, H | 1 |
| Ausserlechner, MJ; Geiger, K; Hagenbuchner, J; Hermann, M; Kiechl-Kohlendorfer, U; Kofler, R; Obexer, P; Rainer, J; Salcher, S; Seiter, MA | 1 |
| Carrasco, R; Cruz, O; de Torres, C; Guillen, A; Lavarino, C; Mañé, S; Mora, J; Parareda, A; Rios, J; Salvador, H; Suñol, M; Vancells, M | 1 |
| Gautschi, M; Häberle, J; Hahn, D; Hu, L; Laemmle, A; Leibundgut, K; Nuoffer, JM; Rüfenacht, V | 1 |
| Li, Z; Thiele, CJ; Tong, J; Tong, Y; Zhang, Y | 1 |
| Brisse, HJ; Canale, S; Elie, C; Galmiche-Rolland, L; Irtan, S; Le Cossec, C; Michon, J; Minard-Colin, V; Sarnacki, S; Schleiermacher, G; Valteau-Couanet, D | 1 |
| Barneda-Zahonero, B; Carriba, P; Coccia, E; Comella, JX; Galenkamp, KM; Lopez-Soriano, J; Moubarak, RS; Planells-Ferrer, L; Segura, MF; Urresti, J | 1 |
| Doktorova, H; Eckschlager, T; Groh, T; Hrabeta, J; Khalil, MA; Stiborova, M | 1 |
| Berthold, F; Peinemann, F; Tushabe, DA; van Dalen, EC | 1 |
| Ashikaga, T; Bachmann, AS; Bergendahl, G; Bond, JP; Eslin, D; Ferguson, W; Gerner, EW; Higgins, T; Hiramatsu, K; Kaplan, J; Kawakita, M; Kraveka, JM; MacArthur, RB; Mitchell, D; Moriya, SS; Neville, K; Parikh, NS; Roberts, W; Saulnier Sholler, GL; Sender, L; VanderWerff, A; Wada, RK | 1 |
| Aguilar, C; Rocha-Zavaleta, L; Vazquez-Mellado, MJ | 1 |
| Qian, J; Sun, M; Wang, L; Yin, Z; Zhang, H | 1 |
| Elborai, Y; Elhaddad, A; Hafez, H; Hammad, M; Hussein, H; Lehmann, L; Moussa, EA | 1 |
| Aplenc, R; Bagatell, R; Desai, AV; Fisher, BT; Getz, K; Huang, V; Li, Y; Mante, A; Seif, AE | 1 |
| Sablauer, A; Shirinifard, A; Thiagarajan, S; Vogel, P | 1 |
| Choi, YB; Koo, HH; Lee, JW; Lee, NH; Son, MH; Sung, KW; Yi, E; Yoo, KH | 1 |
| Berthold, F; Peinemann, F; van Dalen, EC | 1 |
| Bagatell, R; Bunin, NJ; Desai, AV; Grupp, SA; Heneghan, MB; Li, Y; Seif, AE | 1 |
| Colla, R; De Ciucis, C; Domenicotti, C; Fenoglio, D; Furfaro, AL; Izzotti, A; Marengo, B; Passalacqua, M; Pronzato, MA; Pulliero, A; Ravera, S; Ricciarelli, R; Speciale, A; Traverso, N | 1 |
| Fang, J; Guo, H; Li, Y; Liu, L; Qi, K; Xiong, X; Zhang, C | 1 |
| Cao, WM; Chen, Z; Dou, J; Guan, S; Liu, S; Nuchtern, JG; Pang, JC; Patel, R; Shi, Y; Vasudevan, SA; Wang, L; Wang, Y; Xu, X; Yang, J; Yang, T; Yao, D; Yu, Y; Zhang, H; Zhao, Y | 1 |
| Buxton, N; Pilling, D; Pizer, B; Wilkins, S | 1 |
| Castleberry, R; Kletzel, M; Kretschmar, C; London, WB; Marcus, R; Murray, K; Zage, PE; Zhang, Y | 1 |
| Bourgeois, JM; Hodson, I; Macdonald, P; Midia, M; Mullah-Ali, A; Portwine, C; Ramsay, JA | 1 |
| Adkins, ES; Attiyeh, EF; Gerbing, RB; Haas-Kogan, D; London, WB; Maris, JM; Matthay, KK; Park, JR; Reynolds, CP; Seeger, RC; Villablanca, JG | 1 |
| Cai, X; Liu, X | 1 |
| Fujino, A; Honna, T; Kumagai, M; Kuroda, T; Masaki, H; Matsuoka, K; Morikawa, N; Nakagawa, A; Saeki, M | 1 |
| Gutweiler, JR; Kim, HB; Kozakewich, HP; Marcus, KJ; Shamberger, RC; Weldon, CB; Yu, DC | 1 |
| Cheung, NK; Jhanwar, SC; Kramer, K; Kushner, BH; Modak, S; Qin, LX; Yataghena, K | 1 |
| Ausserlechner, M; Böck, G; Geiger, K; Hagenbuchner, J; Obexer, P; Porto, V; Sachsenmaier, N; Seifarth, C; Unterkircher, T | 1 |
| Bénard, J; Duros, C; Gross, N; Meier, R; Mühlethaler-Mottet, A; Raguénez, G | 1 |
| Day, TW; Safa, AR; Wu, CH | 1 |
| Boddy, AV; Cole, M; Ellershaw, C; Errington, J; Gerrard, M; Pearson, AD; Veal, GJ; Whyman, G | 1 |
| Akhurst, TJ; Cheung, NK; Kramer, K; Kushner, BH; Modak, S | 1 |
| Buffa, P; Castellano, A; Clerico, A; Conte, M; D'Ippolito, C; De Bernardi, B; Di Cataldo, A; Fagnani, AM; Garaventa, A; Gigliotti, AR; Granata, C; Parodi, S; Prete, A; Provenzi, M; Rizzo, A; Sementa, AR; Sorrentino, S; Tonini, GP | 1 |
| Fernandez, CV; Golobi, M; Gundogan, M; Irie, T; Luna-Fineman, S; Magee, JF; Quackenbush, KE | 1 |
| Biamonte, R; Ceniti, S; Conforti, S; De Simone, R; Filice, A; Liguori, V; Manfredi, C; Mastroianni, C; Palazzo, S; Patitucci, G; Rovito, A; Turano, S; Viscomi, C | 1 |
| Bensimhon, P; Kreissman, SG; London, WB; Matthay, KK; Park, JR; Seeger, R; Sender, LS; Villablanca, JG; Yap, JS | 1 |
| Feng, C; Liu, Y; Tang, SQ; Wang, JW; Yang, G | 1 |
| He, Q; Wang, D; Yang, B; Zhang, L; Zhang, X; Zhu, Q | 1 |
| Bakhshi, S; Malik, PS | 1 |
| Tonini, GP | 1 |
| Aoyama, M; Asai, K; Kataoka, H; Kubota, E; Tada, T | 1 |
| Baker, DL; Buxton, A; Castleberry, RP; Cohn, SL; London, WB; Look, AT; Maris, JM; Matthay, KK; Reynolds, CP; Sandler, A; Schmidt, ML; Seeger, RC; Shamberger, RC; Shimada, H; Stram, D | 1 |
| Aguilera, D; Das, CM; Gopalakrishnan, V; Lee, D; Taylor, P; Wolff, JE; Zage, PE | 1 |
| Chung, DH; Gillory, LA; Kang, J; Paul, P; Qiao, J | 1 |
| Castellano, A; De Ioris, MA; De Pasquale, MD; De Vito, R; Donfrancesco, A; Garganese, MC; Ilari, I; Inserra, A; Jenkner, A; Locatelli, F; Natali, G; Ravà, L | 1 |
| Hadjidaniel, MD; Reynolds, CP | 1 |
| Kumabe, T; Niizuma, H; Osawa, S; Saito, R; Sonoda, Y; Tominaga, T; Watanabe, M | 1 |
| Bomken, S; Chong, L; Cole, M; Davies, B; McDermott, M; Tweddle, DA; Wood, KM | 1 |
| Ferreti Bonan, PR; Martelli-Júnior, H; Miranda Soares, PB; Pereira DE Souza, W; Quirino Filho, S | 1 |
| De Ciucis, C; Domenicotti, C; Marengo, B; Marinari, UM; Nitti, M; Passalacqua, M; Pronzato, MA; Ricciarelli, R; Zingg, JM | 1 |
| Di Giannatale, A; Mastrangelo, S; Riccardi, R; Rufini, V; Ruggiero, A | 1 |
| Hirao, N; Nose, Y; Saeki, K; Takasawa, R; Tanuma, S | 1 |
| Li, Z; Nakamura, K; Oh, DY; Thiele, CJ | 1 |
| Huang, DS; Liu, XC; Wu, YP; Yang, YP; Zhang, WL; Zhang, Y | 1 |
| Boldorini, R; Canonico, PL; Di Lisa, F; Drago, V; Galli, U; Genazzani, AA; Kaludercic, N; Maldi, E; Travelli, C; Tron, GC | 1 |
| Baba, M; Kato, K; Kodama, T; Kudo, T; Maruyama, D; Morihara, T; Okochi, M; Sadik, G; Tagami, S; Takeda, M; Tanaka, T; Yanagida, K | 1 |
| Lu, CW; Ma, LY; Tong, HX; Wang, QS | 1 |
| Cui, H; Cui, ZB; Gong, XY; Hao, XW; Ke, XX; Li, T; Wan, JH; Wang, L; Xiang, Z; Xu, M | 1 |
| Furuya, T; Ikeda, T; Inoue, M; Kaneda, H; Koshinaga, T; Maebayashi, T; Masuko, T; Mugishima, H; Ohashi, K; Sugito, K; Yagasaki, H | 1 |
| Abdel Rahman, H; El Debawy, E; Ezzat, S; Mostafa, NE; Moussa, EA; Rayan, Ael R; Yones, A; Zekri, WZ | 1 |
| Baldeyroux, B; Hamtiaux, L; Lambert, DM; Lansiaux, A; Matuszak, N; Muccioli, GG; Poupaert, JH | 1 |
| Domenicotti, C; Fenoglio, D; Furfaro, AL; Macay, JR; Marengo, B; Marinari, UM; Nitti, M; Parodi, A; Pronzato, MA; Traverso, N | 1 |
| Ausserlechner, MJ; Hagenbuchner, J; Hausott, B; Hermann, M; Kuznetsov, A; Obexer, P | 1 |
| Attayan, N; Li, Z; Ramalingam, S; Thiele, CJ; Yan, S | 1 |
| Li, Y; Xiong, H; Yang, DQ | 1 |
| Bray, IM; Bryan, K; Creevey, L; Davidoff, AM; Fay, J; Lynch, J; Meehan, M; O'Meara, A; Ryan, J; Stallings, RL; Tivnan, A; Tracey, L | 1 |
| Faden, AI; Hanscom, M; Piao, CS; Sabirzhanov, B; Stoica, BA | 1 |
| Basu, EM; Cheung, NK; Kramer, K; Kushner, BH; Modak, S; Roberts, SS | 2 |
| Ngok-Ngam, P; Satayavivad, J; Thiantanawat, A; Watcharasit, P | 1 |
| Boldrini, R; Castellano, A; Contoli, B; Corneli, T; Crocoli, A; DE Ioris, MA; DE Pasquale, MD; DE Sio, L; Garganese, MC; Jenkner, A; Pessolano, R; Serra, A | 1 |
| Eckschlager, T; Groh, T; Hrabeta, J; Poljakova, J; Stiborova, M | 1 |
| Mendonça-Torres, MC; Roberts, SS | 1 |
| Ballerini, S; Bellincampi, L; Bernardini, S; Cortese, C; Federici, G; Pastore, A; Ranalli, M | 1 |
| Dawson, G; Dawson, PE; Dawson, SA; Marinzi, C | 1 |
| Brodeur, GM; Camoratto, AM; Eggert, A; Evans, AE; Foster, P; Hishiki, T; Ho, R; Ikegaki, N; Minturn, JE | 1 |
| Jaboin, J; Kaplan, DR; Kim, CJ; Thiele, CJ | 1 |
| Iwafuchi, M; Kaneko, M; Kawa, K; Mugishima, H; Ohnuma, N; Sawada, T; Suita, S; Tsuchida, Y; Yamamoto, K | 1 |
| Berger, C; Bernard, JL; Coze, C; Frappaz, D; Michon, J; Perol, D; Philip, T; Zucker, JM | 1 |
| Cui, H; Ding, HF; Schroering, A | 1 |
| Cheung, NK; Kramer, K; Kushner, BH; Larson, SM; Yeh, SD | 1 |
| Gaedicke, G; Huebener, N; Jikai, J; Lange, B; Lode, HN; Schroeder, U; Shabat, D; Shamis, M; Wenkel, J; Wrasidlo, W | 1 |
| Gaedicke, G; Huebener, N; Jikai, J; Lange, B; Lode, HN; Schroeder, U; Strandsby, A; Wenkel, J; Wrasidlo, W | 1 |
| Bergeron, C; Chastagner, P; Hartmann, O; Mechinaud, F; Michon, J; Rubie, H; Schleiermacher, G | 1 |
| Alfaro, PA; Goto, H; Kohn, DB; Pepper, KA; Petersen, D; Reynolds, CP; Yang, B | 1 |
| Clarke, E; Glaser, AW; Picton, SV | 1 |
| Chen, XQ; He, YJ; Lin, TY; Liu, DG; Su, YS; Sun, XF | 1 |
| Karlsson, J; Påhlman, S; Pörn-Ares, I; Øra, I | 1 |
| Castellano, A; Cozza, R; De Laurentis, C; De Sio, L; Deb, G; Dominici, C; Donfrancesco, A; Fidani, P; Ilari, I; Inserra, A; Jenkner, A; Milano, GM | 1 |
| Gräslund, A; Jarvet, J; Kogner, P; Lindskog, M; Spenger, C | 1 |
| Ikarashi, Y; Imai, C; Kakihara, T; Tanaka, A; Uchiyama, M; Watanabe, A | 1 |
| Sugiura, H; Suzuki, Y; Takahashi, M; Yamada, K | 1 |
| Cheung, NK; Kramer, K; Kushner, BH; LaQuaglia, MP; Modak, S; Yataghene, K | 1 |
| Bergeron, C; Bernard, F; Boneu, A; Bouzy, J; Chastagner, P; Coze, C; Hartmann, O; Michon, J; Perel, Y; Plantaz, D; Rodary, C; Rubie, H; Valteau-Couanet, D | 1 |
| Bellincampi, L; Bernardini, S; Biroccio, A; Federici, G; Poland, J; Schnölzer, M; Sinha, P; Urbani, A | 1 |
| Kekre, N; McLachlan, A; McNulty, J; Pandey, S | 1 |
| Debes, A; Göbel, U; Wessalowski, R; Willers, R | 1 |
| Forbes, TJ; Paules, M; Singh, HR; Zilberman, MV | 1 |
| Johnson, CS; Kreissman, SG; Pradhan, KR; Sender, LS; Vik, TA | 1 |
| Bagatell, R; Bowman, LC; Brodeur, GM; Castleberry, R; Cohn, SL; Frantz, C; Joshi, V; London, WB; Look, AT; Rao, PV; Rumcheva, P; Thorner, P | 1 |
| Chan, EL; Collins, MH; Emery, KH; Gelfand, MJ; Gruppo, RA; Harris, RE | 1 |
| Franc, B; Groshen, S; Horn, B; Maris, JM; Matthay, KK; Reynolds, CP; Seeger, RC; Tan, JC; Twomey, E; Veatch, J; Villablanca, JG; Yanik, GA | 1 |
| Cheung, IY; Cheung, NK; Kramer, K; Kushner, BH; Modak, S | 1 |
| Couturier, J; de Cremoux, P; Delattre, O; Doz, F; Fehlbaum, P; Jourdan-Da-Silva, N; Klijanienko, J; Michon, J; Mosseri, V; Schleiermacher, G; Tran-Perennou, C; Vielh, P | 1 |
| Li, Z; Liu, Z; Thiele, CJ; Woo, CW; Zhang, J | 1 |
| Budnick, A; Cheung, NK; Kramer, K; Kushner, BH; Modak, S | 1 |
| Danks, MK; Hatfield, MJ; Lee, RE; Potter, PM; Qi, J; Remack, JS; Virga, KG; Yoon, KJ | 1 |
| Azuhata, T; Griffith, TS; Miller, M; Sandler, AD; Scott, D | 1 |
| Berry, WS; Diller, LR; Guinan, EC; Kalish, LA; Lehmann, LE; McDaniel, S | 1 |
| Dive, C; Estlin, EJ; Hussein, D; Makin, GW | 1 |
| Al-Asaad, TG; Al-Sulami, GA; Atra, AA; Elimam, NA; Fayea, NY; Felimban, SK; Khattab, TM | 1 |
| Armstrong, MB; Bian, X; Castle, VP; Kwok, RP; Liu, Y; Opipari, AW; Ratanaproeksa, AB; Shao, F; Subramanian, C; Yu, VC | 1 |
| Aoyama, C; Hosoya, R; Kamiya, T; Kato, I; Manabe, A; Ogawa, C; Ozawa, M; Takahashi, H; Takusagawa, A; Yokoyama, K | 1 |
| Ellershaw, C; Kohler, JA; Machin, D | 1 |
| Berthold, F; Hero, B; Klingebiel, T; Längler, A; Simon, T | 1 |
| Fukushima, T; Kumagai, M; Shichino, H | 1 |
| Biagiotti, T; Carbone, MV; D'Amico, M; Fredducci, D; Giunti, S; Marzi, I; Olivotto, M; Wanke, E | 1 |
| Lu, CW; Ma, L; Tong, HX; Zhang, JH | 1 |
| Brunetti, E; Bucci, B; Cannizzaro, A; Martinelli, M; Misiti, S; Verga Falzacappa, CV | 1 |
| Berthold, F; Claviez, A; Frühwald, MC; Harnischmacher, U; Hero, B; Jorch, N; Längler, A; Simon, T | 1 |
| Matsui, H; Tada, M; Takahata, K; Tomizawa, K; Wu, Y | 1 |
| Davicioni, E; Ji, L; Keshelava, N; Reynolds, CP; Sposto, R; Triche, TJ; Wan, Z | 1 |
| Gullbo, J; Johnsen, JI; Kogner, P; Larsson, R; Lewensohn, R; Lindskog, M; Lövborg, H; Ponthan, F; Segerström, L; Sveinbjörnsson, B; Viktorsson, K; Wickström, M | 1 |
| Gabel, SF; Liu, J; Milam, MR; Milam, RA; Ramirez, PT | 1 |
| Li, Z; Tan, F; Thiele, CJ | 1 |
| Cheung, NK; Choi, JK; Felix, CA; Jhanwar, SC; Kolaris, CP; Osheroff, N; Robinson, BW | 1 |
| Cheerva, AC; Gross, TG; Kadota, RP; Levine, JE; Ozkaynak, MF; Richards, MK; Rozans, MK; Sahdev, I; Shaw, PJ | 1 |
| Bianchi, G; Lee, C; Longo, VD; Madia, F; Raffaghello, L; Safdie, FM; Wei, M | 1 |
| Bonilla, MA; Cheung, NK; Eddy, J; Gerald, WL; Heller, G; Kushner, BH; LaQuaglia, MP; Lindsley, K; Rosenfield, N; Yeh, S | 1 |
| Berger, M; Chassagne, J; de Lumley, L; Deméocq, F; Kanold, J; Lutz, P; Malpuech, G; Plantaz, D; Rapatel, C; Vannier, JP | 1 |
| Endo, M; Tanosaki, R | 1 |
| Bagnulo, S; Carli, M; Casale, F; De Bernardi, B; De Sio, L; Deb, G; Donfrancesco, A; Helson, L; Mancini, A; Nigro, M | 1 |
| Lowis, SP; Newell, DR; Pearson, AD | 1 |
| Cairo, MS | 1 |
| Fujisawa, I; Hyakuna, K; Kadota, E; Kajimura, K; Kumegawa, Y; Marusawa, H; Seto, S; Takaya, H; Yamashita, Y | 1 |
| Cowie, FJ; Dick, G; Flanagan, RJ; Judson, I; McCarthy, PT; Phillips, M; Pinkerton, CR | 1 |
| Claycamp, HG; Kagan, VE; Pitt, BR; Quinn, PJ; Schor, NF; Tyurin, VA; Tyurina, YY; Yalowich, JC | 1 |
| Castle, VP; Cooper, MJ; Dole, MG; Jasty, R; Nuñez, G; Thompson, CB | 1 |
| Colvin, OM; Frenkel, E; Kamen, BA | 1 |
| Bender-Götze, C; Burdach, S; Ebell, W; Friedrich, W; Herrmann, F; Klingebiel, T; Koscielniak, E; Kremens, B; Schmid, H; Siegert, W | 1 |
| Bowman, LC; McLeod, HL; Relling, MV; Santana, VM | 1 |
| Crist, WM; Pratt, CB; Pui, CH; Rivera, GK; Santana, VM | 1 |
| Davidson, A; Lewis, I; Pearson, AD; Pinkerton, CR; Stevens, MC | 1 |
| Bonilla, MA; Canete, A; Cheung, IY; Cheung, NK; Heller, G; Kushner, B; Larson, SM; Yeh, SJ | 1 |
| Bloch, CA; Castle, VP; Dole, M; Maybaum, J; Merchant, AK; Nuñez, G; Rode, CK | 1 |
| Angioni, A; Boglino, C; Cozza, R; Deb, G; Donfrancesco, A; Helson, L; Jenkner, A; Landolfo, A; Maurizio, C | 1 |
| Cole, M; Lowis, SP; Newell, DR; Pearson, AD | 1 |
| Campbell, LA; Harris, RE; Matthay, KK; Seeger, RC; Villablanca, JG | 1 |
| Chastagnier, P; Courbon, B; De Cervens, C; De Valck, C; Landman, J; Méresse, V; Michon, J; Perel, Y; Rubie, H; Vassal, G | 1 |
| Berthold, F; Boos, J; Euting, T; Jürgens, H; Krümpelmann, S; Schulze-Westhoff, P | 1 |
| Fukuda, M; Horibe, K; Matsumoto, K; Miyajima, Y; Mori, H; Numata, S | 1 |
| Boneu, A; Hartmann, O; Hattchouel, JM; Lumbroso, J; Robert, A; Rodary, C; Rubie, H; Suc, A | 1 |
| Benhamou, E; Bonnay, M; Couanet, D; Hartmann, O; Plantaz, D; Pondarré, C; Valteau-Couanet, D; Vassal, G | 1 |
| Ardouin, P; Bénard, J; Bissery, MC; Boland, I; Bressac-de-Paillerets, B; Gouyette, A; Gyergyay, F; Morizet, J; Terrier-Lacombe, MJ; Vassal, G; Vénuat, AM | 1 |
| Angio, GD; August, CS; Bayever, E; Bunin, N; Evans, AE; Goldwein, J; Kamani, N; Leahey, A; Zusman, J | 1 |
| Livingstone, A; Mairs, RJ | 1 |
| Avet-Loiseau, H; Baranzelli, MC; Bénard, J; Bergeron, C; Chastagner, P; Courbon-Collet, B; Coze, C; Delattre, O; Favrot, M; Frappaz, D; Hartmann, O; Lemerle, J; Michon, J; Perel, Y; Peyroulet, MC; Plantaz, D; Rubie, H; Sommelet, D; Thyss, A; Vannier, JP | 1 |
| Bernardi, R; Poirier, GG; Rossi, L; Scovassi, AI | 1 |
| Arango, HA; Decesare, SL; Fiorica, JV; Kalter, CS; Lyman, GH; Spellacy, WN | 1 |
| Fales, I; Hrubá, A; Kavan, P; Kobylka, P; Matĕjcková, S; Skala, JP; Starý, J; Vodvárková, S | 1 |
| Debatin, KM; Friesen, C; Fulda, S; Herr, I; Sieverts, H | 1 |
| Beck, D; Béhar, C; Bergeron, C; Bernard, JL; Bordigoni, P; Coze, C; Dusol, F; Frappaz, D; Hartmann, O; Leverger, G; Mechinaud, F; Michon, J; Otten, J; Philip, T; Plantaz, D; Plouvier, E; Rubie, H; Zucker, JM | 1 |
| Conejero, C; Dillon-Carter, O; Freed, WJ; Poltorak, M; Tornatore, C | 1 |
| Cinatl, J; Doerr, HW; Driever, PH; Kabickova, H; Kornhuber, B; Kotchetkov, R; Schwabe, D; Vogel, JU | 1 |
| Keshelava, N; Reynolds, CP; Seeger, RC | 1 |
| Cowie, FJ; Pinkerton, CR; Pritchard-Jones, K; Renshaw, J | 1 |
| Baranzelli, MC; Boutard, P; Chastagner, P; Coze, C; de Lumley, L; Frappaz, D; Hartmann, O; Leverger, G; Lutz, P; Margueritte, G; Méchinaud, F; Michon, J; Millot, F; Perel, Y; Peyroulet, MC; Plantaz, D; Rubie, H; Stéphan, JL | 1 |
| Bezvenyuk, Z; Huotari, V; Salminen, A; Solovyan, V; Suuronen, T; Tapiola, T | 1 |
| Hertel, C; Kuner, P | 1 |
| Bernard, JL; Bordigoni, P; Bouffet, E; Cattiaux, E; Coze, C; Hartmann, O; Lemerle, J; Meresse, V; Michon, JM; Philip, T; Rubie, H; Ward, N; Zucker, JM | 1 |
| Groshen, S; Keshelava, N; Reynolds, CP; Seeger, RC | 1 |
| Ronca, F; Yee, KS; Yu, VC | 1 |
| Bezvenyuk, Z; Huotari, V; Salminen, A; Solovyan, V; Tapiola, T | 1 |
| Cheung, NK; Kramer, K; Kushner, BH | 1 |
| Bessho, F; Etoh, T; Honna, T; Iwafuchi, M; Kaneko, M; Kawa, K; Mimaya, J; Miyata, H; Mugishima, H; Nakada, K; Nakamura, T; Nozaki, T; Ohhira, M; Ohnuma, N; Sawada, T; Tsuchida, Y; Yamamoto, K; Yamato, K; Yokoyama, J; Yoshizawa, J | 1 |
| Bella, S; Burnelli, R; Garaventa, A; Locatelli, F; Melchionda, F; Paolucci, G; Pession, A; Prete, A | 1 |
| Hovi, L; Lipsanen, M; Saarinen-Pihkala, UM; Tapanainen, P; Vettenranta, K | 1 |
| Groshen, S; Keshelava, N; Reynolds, CP | 1 |
| Addya, K; Cheung, NK; Felix, CA; Jones, DH; Kushner, BH; Lange, BJ; Leonard, DG; Megonigal, MD; Nowell, PC; Rappaport, EF; Williams, TM; Wilson, RB | 1 |
| Ausema, B; Kamps, W; Kok, JW; Kolk, D; Nijhof, W; Sietsma, H; Veldman, RJ; Vellenga, E | 1 |
| Bonneu, A; Chauvot, P; Edeline, V; Frappaz, D; Giammarile, F; Gomez, F; Siles, S; Wioland, M | 1 |
| Berman, SA; Bursztajn, S; Feng, JJ; Nanda, A | 2 |
| Kolehmainen, P; Salminen, A; Suuronen, T | 1 |
| Fernandez, MC; Gerbing, RR; Krailo, MD; Matthay, KK | 1 |
| Bernassola, F; Lovat, PE; Malcolm, AJ; Melino, G; Pearson, AD; Piacentini, M; Ranalli, M; Redfern, CP; Tilby, M | 1 |
| Kirov, I; Lones, MA; Neudorf, S; Said, JW; Shintaku, IP | 1 |
| Chresta, CM; Eden, TO; Hickman, JA; Rodriguez-Lopez, AM; Xenaki, D | 1 |
| Kuusisto, E; Salminen, A; Suuronen, T | 1 |
| Diociaiuti, L; Mastrangelo, R; Mastrangelo, S; Pession, A; Prete, A; Rufini, V; Tornesello, A; Troncone, L | 1 |
| Barbas, CF; Lerner, RA; Lode, HN; Pertl, U; Rader, C; Reisfeld, RA; Shabat, D | 1 |
| Kremens, B; Pütter, S; Trarbach, T; Van Heek-Romanowski, R | 1 |
| Berthold, F; Fichtner, I; Fulda, S; Hero, B | 1 |
| Fukuda, M; Horibe, K; Inaba, J; Kondo, M; Matsumoto, K; Miyajima, Y; Miyashita, Y | 1 |
| Berthold, F; Gahr, M; Hero, B; Hunneman, DH | 1 |
| Abramson, S; Byrnes, M; Cheung, IY; Cheung, NK; Dantis, E; Finn, R; Gerald, W; Gollamudi, S; Heller, G; Kramer, K; Kushner, BH; LaQuaglia, M; Larson, SM; Mora, J; O'Reilly, RJ; Rosenfield, N; Wuest, D; Yeh, S | 1 |
| Cole, M; Ellershaw, C; Lewis, IJ; Pearson, AD; Pinkerton, CR; Tweddle, DA | 1 |
| Baranzelli, MC; Chastagner, P; Coze, C; Frappaz, D; Hartmann, O; Michon, J; Peyroulet, MC; Plantaz, D; Rubie, H | 1 |
| Castello, MA; Maurizi, P; Schiavetti, A; Varrasso, G | 1 |
| Chen, P; Gomer, CJ; Keshelava, N; Luna, MC; Reynolds, CP; Triche, TJ; Waidyaratne, SN; Zuo, JJ | 1 |
| Al-Mobarak, M; Badawood, S; Balawi, I; Meir, HM; Nayel, H; Yousef, MK | 1 |
| Ashley, DM; Chow, CW; Gray, AZ; Hawkins, CJ; Riffkin, CD | 1 |
| Cho, S; Dawson, G; Dawson, PE | 1 |
| Naito, K; Oba, K; Wada, T; Yamaguchi, S; Yoshihiro, S | 1 |
| Azuhata, T; Davidoff, A; Fukuzawa, M; Sandler, A; Scott, D; Takamizawa, S; Wen, J | 1 |
| Guidos, BJ; Selvaggi, SM | 1 |
| Agata, H; Fujimoto, T; Hirota, T; Hori, T; Kawai, N; Kitagawa, S; Konno, K; Sawada, K; Tsurusawa, M | 1 |
| Hayashi, Y; Iinuma, K; Imaizumi, M; Ito, E; Kikuta, A; Konno, T; Ohi, R; Shimizu, T; Takano, T; Tsuchiya, S; Watanabe, A | 1 |
| Corbo, M; Cotter, FE; Dean, NM; Fennell, DA; Kuss, BJ; Lau, WM | 1 |
| Austin, CA; Meczes, EL; Pearson, AD; Tilby, MJ | 1 |
| Benchimol, S; Bristow, RG; Gangopadhyay, S; Jalali, F; Peacock, J; Reda, D | 1 |
| Braun, T; Ferrara, JL; Hubers, D; Hutchinson, RJ; Levine, JE; Matthay, KK; Shapiro, B; Shulkin, BL; Sisson, JC; Spalding, S; Yanik, GA | 1 |
| Creamer, K; Flores, Y; Roberts, S; Robie, D; Shoupe, B | 1 |
| Bellman, SC; Brock, PR; Pritchard, J; Yeomans, EC | 1 |
| Craft, AW; Meller, ST; Pearson, AD; Pinkerton, CR; Reid, MM | 1 |
| Bouffet, E; Brugiere, L; Chastagner, P; Frappaz, D; Gentet, JC; Hartmann, O; Lejars, O; Michon, J; Rubie, H; Sariban, E | 2 |
| Bowman, LC; Brenner, MK; Mirro, J; Santana, VM; Schell, MJ; Thompson, EI; Williams, R | 1 |
| Amici, A; Angioni, A; Caniglia, M; De Sio, L; Deb, G; Dominici, C; Donfrancesco, A; Fidani, P; Helson, L | 1 |
| D'Angio, G; Evans, A; Scher, C | 1 |
| Craft, AW; Gordon, SJ; Pearson, AD; Reid, MM | 1 |
| Corbett, R; Kingston, J; Lewis, I; McElwain, T; Meller, S; Pinkerton, R; Pritchard, J | 1 |
| Becton, DL; Berry, DH; Kletzel, M | 1 |
| Watts, RG | 1 |
| Fujita, K; Hibi, S; Imashuku, S; Miyake, M; Nakajima, F; Todo, S | 1 |
| Gearhart, JP; Jeffs, RD; Leonard, MP | 1 |
| Bernard, JL; Bouffet, E; Coze, C; Gentet, JC; Lopez, M; Michon, J; Philip, I; Philip, T; Zucker, JM | 1 |
| Biron, P; Bouffet, E; Brunat-Mentigny, M; Chauvin, F; Ladenstein, R; Lasset, C; Philip, I; Philip, T | 1 |
| Cheung, NK; Gulati, SC; Kushner, BH; LaQuaglia, M; Mandell, LR; O'Reilly, RJ | 1 |
| Kaneko, M; Kaneko, S; Ohkawa, H | 1 |
| Haase, GM; Hammond, GD; O'Leary, MC; Ramsay, NK; Romansky, SG; Seeger, RC; Stram, DO | 1 |
| Feig, SA; Harris, R; Matthay, KK; Moss, TJ; Ramsay, N; Reynolds, CP; Seeger, RC; Selch, M; Villablanca, JG | 1 |
| Castello, MA; Clerico, A; Cozza, R; De Laurentis, C; De Sio, L; Deb, G; Dominici, C; Donfrancesco, A; Properzi, E; Schiavetti, A | 1 |
| Cheung, NK; Gulati, SC; Heller, G; Kushner, BH; O'Reilly, RJ | 1 |
| Aihara, T; Hanada, R; Hayashi, Y; Hirata, A; Imaizumi, S; Inaba, T; Miyakawa, T; Sugawara, T; Yaginuma, A; Yamamoto, K | 1 |
| Akiyama, Y; Ito, M; Kamiya, H; Kawa, K; Mikawa, H; Miyazaki, S; Sakurai, M; Tujino, G; Ueda, K | 1 |
| Breatnach, F; Broadbent, V; Craft, AE; Hartmann, O; Morris-Jones, P; Pearson, AD; Pinkerton, CR; Pritchard, J; Wallendszus, KR; Zucker, JM | 1 |
| Cheung, NK; Kushner, BH; LaQuaglia, M; O'Reilly, RJ | 1 |
| Anas, N; Cairo, MS; Sender, L; Siegel, S | 1 |
| Fossati-Bellani, F; Gandola, L; Gasparini, M; Gianni, C; Lattuada, A; Lombardi, F; Rottoli, L | 1 |
| Cook, JM; Florence, AT; Russell, J; Wheldon, TE | 1 |
| Bouffet, E; Brunat-Mentigny, M; Carrie, C; Farge, A; Gentet, JC; Kremens, B; Meziane, F; Philip, T; Zucker, JM | 1 |
| Helson, L | 1 |
| Hovi, L; Mäkipernaa, A; Maunuksela, EL; Perkkiö, M; Rajantie, J; Siimes, MA; Wikström, S | 1 |
| Beaujean, F; Behard, C; Benhamou, E; Deville, A; Flamant, F; Hartmann, O; Kalifa, C; Lejars, O; Patte, C; Thyss, A | 1 |
| Breatnach, F; Hartmann, O; Philip, T; Pinkerton, CR; Zucker, JM | 1 |
11 review(s) available for etoposide and Neuroblastoma
| Article | Year |
|---|---|
Rapid COJEC versus standard induction therapies for high-risk neuroblastoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cisplatin; Cyclophosphamide; Drug Administration Schedule; Etoposide; Humans; Induction Chemotherapy; Infant; Neuroblastoma; Randomized Controlled Trials as Topic; Vincristine | 2015 |
Rapid COJEC Induction Therapy for High-risk Neuroblastoma Patients - Cochrane Review.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Humans; Male; Neoadjuvant Therapy; Neuroblastoma; Randomized Controlled Trials as Topic; Risk Assessment; Survival Rate; Vincristine; Young Adult | 2016 |
Paraspinal synovial sarcoma as an unusual postradiation complication in pediatric abdominal neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 18; Chromosomes, Human, X; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Infant; Lumbar Vertebrae; Mechlorethamine; Muscle Neoplasms; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Neuroblastoma; Oncogene Proteins, Fusion; Remission Induction; Retroperitoneal Neoplasms; Sarcoma, Synovial; Spinal Stenosis; Translocation, Genetic; Vincristine | 2008 |
Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Carboplatin; Child; Child, Preschool; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Ifosfamide; Infant; Male; Neuroblastoma; Retrospective Studies; Salvage Therapy; Soft Tissue Neoplasms; Young Adult | 2013 |
Favorable histology, MYCN-amplified 4S neonatal neuroblastoma.
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Gene Amplification; Genes, myc; Genes, Neoplasm; Hepatomegaly; Humans; Infant, Newborn; Isotretinoin; Liver Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Neuroblastoma; Prognosis; Remission Induction; Risk Factors | 2007 |
[Myeloablative chemotherapy with autologous bone marrow and/or peripheral blood stem cell transplantation in children with high-risk solid tumor].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Carboplatin; Child; Combined Modality Therapy; Cryopreservation; Doxorubicin; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Kidney Neoplasms; Neoplasms; Neuroblastoma; Rhabdomyosarcoma; Wilms Tumor | 1995 |
The use of ifosfamide, carboplatin, and etoposide in children with solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Etoposide; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Neoplasms; Neuroblastoma; Neutropenia; Sarcoma; Thrombocytopenia; Wilms Tumor | 1995 |
Epipodophyllotoxins in the treatment of childhood cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytarabine; Etoposide; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Neoplasms; Neoplasms, Second Primary; Neuroblastoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Teniposide | 1994 |
Management of chemotherapy in a pregnancy complicated by a large neuroblastoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Nausea; Neuroblastoma; Neutropenia; Ondansetron; Pregnancy; Pregnancy Complications, Neoplastic; Recombinant Proteins; Retroperitoneal Neoplasms; Vomiting | 1994 |
Post-transplant lymphoproliferative disorder after autologous peripheral stem cell transplantation in a pediatric patient.
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cisplatin; Colonic Diseases; Combined Modality Therapy; Cyclophosphamide; Cytomegalovirus Infections; Doxorubicin; Duodenal Ulcer; Epstein-Barr Virus Infections; Etoposide; Gastrointestinal Hemorrhage; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppressive Agents; Lung Neoplasms; Lymphatic Metastasis; Lymphoma, Large B-Cell, Diffuse; Male; Neuroblastoma; Orbital Neoplasms; Prion Diseases; Transplantation Conditioning; Transplantation, Autologous; Ulcer; Vincristine | 2000 |
Unique management of stage 4S neuroblastoma complicated by massive hepatomegaly: case report and review of the literature.
Topics: Abdominal Muscles; Adrenal Cortex Hormones; Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Breast Feeding; Carboplatin; Combined Modality Therapy; Enteral Nutrition; Etoposide; Hemorrhage; Hepatomegaly; Humans; Infant; Laparotomy; Liver Neoplasms; Lung Diseases; Male; Neoplasm Staging; Neuroblastoma; Occlusive Dressings; Pancytopenia; Parenteral Nutrition, Total; Positive-Pressure Respiration; Postoperative Complications; Sepsis; Surgical Mesh; Vacuum | 2002 |
59 trial(s) available for etoposide and Neuroblastoma
| Article | Year |
|---|---|
Incorporation of high-dose
Topics: 3-Iodobenzylguanidine; Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Etoposide; Humans; Induction Chemotherapy; Infant; Melphalan; Neuroblastoma; Stem Cell Transplantation; Thiotepa; Transplantation, Autologous; Young Adult | 2017 |
Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma.
Topics: Administration, Metronomic; Adult; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Humans; Infant; Male; Neoplasm Recurrence, Local; Neuroblastoma; Pilot Projects; Survival Rate; Vinblastine | 2017 |
High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Neuroblastoma; Retrospective Studies; Survival Rate; Thrombotic Microangiopathies; Transplantation, Autologous | 2018 |
Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Child; Child, Preschool; Comparative Genomic Hybridization; Etoposide; Female; Humans; Induction Chemotherapy; Infant; Japan; Male; Melphalan; Neuroblastoma; Prospective Studies; Survival Rate; Treatment Outcome | 2018 |
Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Filgrastim; Gene Amplification; Hepatomegaly; Humans; Infant; Infant, Newborn; Loss of Heterozygosity; Male; N-Myc Proto-Oncogene Protein; Neoplasm Staging; Neuroblastoma; Risk Factors; Survival Rate | 2019 |
Treatment of children over the age of one year with unresectable localised neuroblastoma without MYCN amplification: results of the SIOPEN study.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Gene Amplification; Humans; Infant; Male; N-Myc Proto-Oncogene Protein; Neuroblastoma; Nuclear Proteins; Oncogene Proteins; Survival Analysis; Vincristine | 2013 |
A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma.
Topics: Adolescent; Child; Child, Preschool; Eflornithine; Etoposide; Female; Humans; Infant; Male; Neuroblastoma; Ornithine Decarboxylase; Ornithine Decarboxylase Inhibitors; Phenotype; Polyamines; Recurrence; Safety; Treatment Outcome | 2015 |
Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group.
Topics: Bone Marrow Purging; Bone Marrow Transplantation; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Infant; Isotretinoin; Neuroblastoma; Radiotherapy; Risk; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 2009 |
Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Etoposide; Female; Follow-Up Studies; Humans; Infant; Infusions, Intravenous; Male; Metabolic Clearance Rate; Neuroblastoma; Neutropenia; Remission Induction; Thrombocytopenia; Treatment Outcome | 2010 |
Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology Group.
Topics: Antineoplastic Agents; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Infant; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Neuroblastoma; Peripheral Blood Stem Cell Transplantation; Vincristine | 2010 |
Outcome after reduced chemotherapy for intermediate-risk neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Infant; Intention to Treat Analysis; Neoplasm Staging; Neuroblastoma; Prospective Studies; Survival Analysis; Treatment Outcome | 2010 |
Did salvage ICE chemotherapy improve the outcome in primary resistant/relapsing stage III/IV neuroblastoma?
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Ifosfamide; Infant; Kaplan-Meier Estimate; Male; Neoplasm Recurrence, Local; Neuroblastoma; Salvage Therapy; Treatment Outcome | 2011 |
Comparison of two different conditioning regimens before autologous transplantation for children with high-risk neuroblastoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Gene Amplification; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Melphalan; N-Myc Proto-Oncogene Protein; Neuroblastoma; Nuclear Proteins; Oncogene Proteins; Risk Factors; Thiotepa; Transplantation Conditioning | 2012 |
The LMCE5 unselected cohort of 25 children consecutively diagnosed with untreated stage 4 neuroblastoma over 1 year at diagnosis.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cisplatin; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Infant; Male; Melphalan; Neuroblastoma; Peripheral Blood Stem Cell Transplantation; Treatment Outcome | 2002 |
Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cyclophosphamide; Dacarbazine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Ifosfamide; Infant; Male; Neoplasm Recurrence, Local; Neuroblastoma; Palliative Care; Temozolomide; Topotecan; Treatment Outcome | 2004 |
Glomerular dysfunction, independent of tubular dysfunction, induced by antineoplastic chemotherapy in children.
Topics: Acute Disease; Adolescent; Albuminuria; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Creatinine; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Glomerular Filtration Rate; Humans; Kidney Tubules; Leukemia; Lymphoma; Methotrexate; Neoplasms; Neuroblastoma; Osteosarcoma; Proteinuria; Rhabdomyosarcoma; Vincristine | 2004 |
Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma.
Topics: Antibodies; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Gangliosides; Granulocyte Colony-Stimulating Factor; Humans; Immunotherapy; Infant; Male; Neuroblastoma; Risk Factors; Treatment Outcome; Vincristine | 2004 |
Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol.
Topics: 3-Iodobenzylguanidine; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Humans; Infant; Male; Neoplasm Metastasis; Neuroblastoma; Neutropenia; Radiopharmaceuticals; Thrombocytopenia; Treatment Outcome; Vincristine | 2005 |
A novel intensive induction therapy for high-risk neuroblastoma utilizing sequential peripheral blood stem cell collection and infusion as hematopoietic support.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Infant; Linear Models; Male; Neuroblastoma; Peripheral Blood Stem Cell Transplantation; Pilot Projects; Remission Induction; Survival Analysis | 2006 |
Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy.
Topics: Abdominal Neoplasms; Adolescent; Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cisplatin; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Ifosfamide; Infant; Male; N-Myc Proto-Oncogene Protein; Neoplasm Staging; Neuroblastoma; Neutropenia; Nuclear Proteins; Oncogene Proteins; Ploidies; Prognosis; Risk Factors; Treatment Outcome | 2005 |
Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.
Topics: 3-Iodobenzylguanidine; Adolescent; Antineoplastic Agents; Carboplatin; Child; Child, Preschool; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Neuroblastoma; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 2006 |
Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma.
Topics: Antineoplastic Agents; Child, Preschool; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Female; Hearing Loss; Humans; Male; Neuroblastoma | 2006 |
Response to N7 induction chemotherapy in children more than one year of age diagnosed with metastatic neuroblastoma treated in UKCCSG centers.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Infant; Male; Neuroblastoma; Radionuclide Imaging; Remission Induction; Survival Analysis; Vincristine | 2007 |
Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; Etoposide; Female; Humans; Infant; Male; Neoplasm Recurrence, Local; Neuroblastoma; Topotecan; Treatment Outcome | 2007 |
Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Humans; Infant; Infant, Newborn; Male; Neoplasm Recurrence, Local; Neuroblastoma; Topotecan; Treatment Outcome | 2007 |
A pilot study of addition of amifostine to melphalan, carboplatin, etoposide, and cyclophosphamide with autologous hematopoietic stem cell transplantation in pediatric solid tumors-A pediatric blood and marrow transplant consortium study.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bone Neoplasms; Carboplatin; Central Nervous System Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Etoposide; Feasibility Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Hypocalcemia; Kidney Neoplasms; Melphalan; Neoplasms; Neuroblastoma; Pilot Projects; Recurrence; Risk Factors; Sarcoma; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Wilms Tumor | 2008 |
Use of G-CSF alone to mobilize peripheral blood stem cells for collection from children.
Topics: Child; Child, Preschool; Cyclophosphamide; Erythroid Precursor Cells; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Infant, Newborn; Neuroblastoma; Sarcoma, Ewing | 1994 |
Deferoxamine followed by cyclophosphamide, etoposide, carboplatin, thiotepa, induction regimen in advanced neuroblastoma: preliminary results. Italian Neuroblastoma Cooperative Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Child; Child, Preschool; Cyclophosphamide; Deferoxamine; Etoposide; Humans; Infant; Neoplasm Staging; Neuroblastoma; Risk Factors; Thiotepa | 1995 |
Continuous-infusion verapamil with etoposide in relapsed or resistant paediatric cancers.
Topics: Adolescent; Adult; Bone Neoplasms; Child; Child, Preschool; Drug Administration Schedule; Drug Resistance, Multiple; Etoposide; Female; Hodgkin Disease; Humans; Infant; Infusions, Intravenous; Kidney Neoplasms; Male; Neoplasms; Neuroblastoma; Osteosarcoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Rhabdomyosarcoma; Sarcoma, Ewing; Verapamil; Wilms Tumor | 1995 |
High-dose consolidation with local radiation and bone marrow rescue in patients with advanced neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Carmustine; Child; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Follow-Up Studies; Humans; Infant; Melphalan; Neoplasm Recurrence, Local; Neuroblastoma; Radiotherapy, High-Energy; Remission Induction; Survival Rate | 1994 |
Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Catechols; Child; Child, Preschool; Cisplatin; Etoposide; Female; Humans; Infant; Male; Neuroblastoma | 1994 |
D-CECaT: a breakthrough for patients with neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carboplatin; Child; Child, Preschool; Cyclophosphamide; Deferoxamine; Etoposide; Humans; Infant; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Thiotepa | 1993 |
Combined continuous infusion etoposide with high-dose cyclophosphamide for refractory neuroblastoma: a phase II study from the Société Française d'Oncologie Pédiatrique.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Etoposide; Female; Humans; Infant; Infusions, Intravenous; Male; Neuroblastoma | 1993 |
Steady-state levels and bone marrow toxicity of etoposide in children and infants: does etoposide require age-dependent dose calculation?
Topics: Adolescent; Aging; Body Surface Area; Body Weight; Bone Marrow Diseases; Child; Child, Preschool; Dose-Response Relationship, Drug; Etoposide; Humans; Individuality; Infant; Infusions, Intravenous; Neuroblastoma | 1995 |
Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Diarrhea; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Humans; Infant; Infusions, Intravenous; Injections, Intravenous; Male; Melphalan; Neuroblastoma; Neutropenia; Remission Induction; Salvage Therapy; Stomatitis; Transplantation Conditioning; Vincristine | 1996 |
NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric Oncology.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Infant; Infections; Infusions, Intravenous; Leukopenia; Male; Neuroblastoma; Neutropenia; Thrombocytopenia; Treatment Outcome; Vincristine | 1997 |
Unresectable localized neuroblastoma: improved survival after primary chemotherapy including carboplatin-etoposide. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Infant, Newborn; Male; Neuroblastoma; Prognosis; Treatment Outcome; Vincristine | 1998 |
An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Fever; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Infant; Male; Neuroblastoma; Neutropenia; Recombinant Proteins; Treatment Outcome; Vincristine | 1998 |
Oral etoposide for refractory and relapsed neuroblastoma.
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Bone Marrow Neoplasms; Child; Child, Preschool; Drug Administration Schedule; Etoposide; Female; Humans; Male; Neoplasm Recurrence, Local; Neuroblastoma; Treatment Outcome | 1999 |
Phase I study of high-dose thiotepa with busulfan, etoposide, and autologous stem cell support in children with disseminated solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Neuroblastoma; Prognosis; Rhabdomyosarcoma; Sarcoma, Ewing; Thiotepa | 1999 |
A phase I dose escalation of combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with neuroblastoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Ifosfamide; Infant; Infant, Newborn; Male; Neuroblastoma; Neutropenia; Thrombocytopenia; Treatment Outcome | 2000 |
Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy.
Topics: 3-Iodobenzylguanidine; Abdominal Neoplasms; Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Humans; Infant; Infusions, Intravenous; Iodine Radioisotopes; Male; Mediastinal Neoplasms; Neuroblastoma; Radiopharmaceuticals; Treatment Outcome; Vincristine | 2001 |
Preclinical and clinical aspects on the use of amifostine as chemoprotector in neuroblastoma patients.
Topics: Adolescent; Amifostine; Animals; Antineoplastic Agents; Bone Marrow Diseases; Carboplatin; Cell Division; Child; Child, Preschool; Cisplatin; Cross-Over Studies; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Etoposide; Humans; Ifosfamide; Mercaptoethylamines; Mice; Mice, Nude; Neuroblastoma; Neutropenia; Prodrugs; Safety; Thrombocytopenia; Treatment Failure; Tumor Cells, Cultured; Vincristine; Vomiting; Xenograft Model Antitumor Assays | 2001 |
Evaluation of catecholamine metabolites, mIBG scan, and bone marrow cytology as response markers in stage 4 neuroblastoma.
Topics: 3-Iodobenzylguanidine; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Examination; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Disease-Free Survival; Doxorubicin; Etoposide; Homovanillic Acid; Humans; Ifosfamide; Iodine Radioisotopes; Life Tables; Melphalan; Neoplasm Staging; Neuroblastoma; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome; Vanilmandelic Acid; Vincristine; Vindesine | 2001 |
N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Diseases; Chemotherapy, Adjuvant; Child; Child, Preschool; Chromosome Aberrations; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Dose Fractionation, Radiation; Doxorubicin; Etoposide; Gene Amplification; Genes, myc; Humans; Hypothyroidism; Immunization, Passive; Immunoconjugates; Immunoglobulin G; Iodine Radioisotopes; Neoplasm Proteins; Neoplasm Staging; Neuroblastoma; Radioimmunotherapy; Radiotherapy, Adjuvant; Remission Induction; Risk Factors; Survival Analysis; Treatment Outcome; Vincristine | 2001 |
OPEC/OJEC for stage 4 neuroblastoma in children over 1 year of age.
Topics: 3-Iodobenzylguanidine; Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Diseases; Bone Neoplasms; Carboplatin; Child, Preschool; Cisplatin; Cyclophosphamide; Diphosphonates; Disease-Free Survival; Etoposide; Female; Gastrointestinal Diseases; Humans; Incidence; Infant; Iodine Radioisotopes; Kidney Diseases; Male; Neoplasm Staging; Nervous System Diseases; Neuroblastoma; Radionuclide Imaging; Radiopharmaceuticals; Remission Induction; Survival Analysis; Survival Rate; Technetium Compounds; Treatment Outcome; Vincristine | 2001 |
[Phase I study with irinotecan hydrochloride (CPT-11) for advanced neuroblastoma].
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child, Preschool; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Irinotecan; Neuroblastoma | 2001 |
Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma.
Topics: 3-Iodobenzylguanidine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Etoposide; Feasibility Studies; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Neuroblastoma; Pilot Projects; Radiopharmaceuticals; Transplantation, Autologous | 2002 |
Etoposide and carboplatin in neuroblastoma: a French Society of Pediatric Oncology phase II study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Male; Neuroblastoma; Treatment Outcome | 1992 |
Escalating sequential high-dose carboplatin and etoposide with autologous marrow support in children with relapsed solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Central Nervous System Neoplasms; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Combined Modality Therapy; Dose-Response Relationship, Drug; Etoposide; Female; Gastrointestinal Diseases; Hodgkin Disease; Humans; Infusions, Intravenous; Male; Neoplasm Recurrence, Local; Neuroblastoma; Neutropenia; Thrombocytopenia | 1992 |
A phase I trial of high-dose carboplatin and etoposide with autologous marrow support for treatment of relapse/refractory neuroblastoma without apparent bone marrow involvement: use of marker genes to investigate the biology of marrow reconstitution and t
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Carboplatin; Child; Drug Evaluation; Drug Resistance; Etoposide; Genetic Markers; Genetic Vectors; Humans; Informed Consent; Kanamycin Kinase; Neomycin; Neoplasm Recurrence, Local; Neuroblastoma; Phosphotransferases; Recombinant Proteins; Research Design; Transduction, Genetic; Transplantation, Autologous | 1991 |
A phase I trial of high-dose carboplatin and etoposide with autologous marrow support for treatment of stage D neuroblastoma in first remission: use of marker genes to investigate the biology of marrow reconstitution and the mechanism of relapse.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Carboplatin; Child; Drug Evaluation; Drug Resistance; Etoposide; Genetic Markers; Genetic Vectors; Humans; Informed Consent; Kanamycin Kinase; Neomycin; Neoplasm Recurrence, Local; Neuroblastoma; Phosphotransferases; Recombinant Proteins; Research Design; Transduction, Genetic; Transplantation, Autologous | 1991 |
Single or double consolidation treatment according to remission status after initial therapy in metastatic neuroblastoma: first results of LMCE 3 study in 40 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Carmustine; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; France; Humans; Infant; Life Tables; Male; Neuroblastoma; Remission Induction; Reoperation; Survival Analysis; Transplantation, Autologous; Vincristine | 1991 |
A single center experience with bone marrow transplantation for high risk neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Carmustine; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; France; Humans; Infant; Male; Neuroblastoma; Organoplatinum Compounds; Remission Induction; Reoperation; Survival Rate; Teniposide; Vincristine | 1991 |
Intensive chemoradiotherapy and autologous bone marrow transplantation for poor prognosis neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Doxorubicin; Etoposide; Follow-Up Studies; Humans; Infant; Methotrexate; Neuroblastoma; Procarbazine; Prognosis; Transplantation, Autologous; Vincristine; Whole-Body Irradiation | 1991 |
VP 16 carboplatinum in neuroblastoma: a SFOP phase II study. The Société Française d'Oncologie Pédiatrique.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child, Preschool; Drug Evaluation; Etoposide; Female; Humans; Male; Neoplasm Staging; Neuroblastoma | 1991 |
Treatment of pediatric malignant tumors with VP-16. West Japan Pediatric Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Etoposide; Histiocytosis; Humans; Infant; Leukemia, Myeloid, Acute; Lymphoma; Neoplasms; Neuroblastoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1990 |
Clinical trial of continuous infusion verapamil, bolus vinblastine, and continuous infusion VP-16 in drug-resistant pediatric tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Child; Child, Preschool; Clinical Trials as Topic; Etoposide; Humans; Infusions, Intravenous; Leukemia; Liver Neoplasms; Neuroblastoma; Verapamil; Vinblastine | 1989 |
How much progress has been achieved in cancer therapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Drug Therapy; Etoposide; Humans; Medical Oncology; Neoplasms; Neuroblastoma | 1988 |
227 other study(ies) available for etoposide and Neuroblastoma
| Article | Year |
|---|---|
Asymmetrical 2,6-bis(benzylidene)cyclohexanones: Synthesis, cytotoxic activity and QSAR study.
Topics: Antineoplastic Agents; Apoptosis; Benzylidene Compounds; Breast Neoplasms; Cell Proliferation; Cyclohexanones; Drug Screening Assays, Antitumor; Female; Humans; Molecular Structure; Neuroblastoma; Quantitative Structure-Activity Relationship; Structure-Activity Relationship; Tumor Cells, Cultured | 2012 |
Multiple approaches to repurposing drugs for neuroblastoma.
Topics: Bayes Theorem; Cell Line, Tumor; Child; Child, Preschool; Crizotinib; Drug Repositioning; Etoposide; Fingolimod Hydrochloride; Humans; Neuroblastoma; Niclosamide | 2022 |
KMT2A-MAML2 rearrangement emerged and regressed during neuroblastoma therapy without leukemia after 12.8-year follow-up.
Topics: Etoposide; Follow-Up Studies; Gene Rearrangement; Histone-Lysine N-Methyltransferase; Humans; Leukemia; Myeloid-Lymphoid Leukemia Protein; Neuroblastoma; Trans-Activators; Transcription Factors | 2022 |
Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Etoposide; Humans; Irinotecan; Neoplasm Recurrence, Local; Neuroblastoma; Neutropenia; Retrospective Studies | 2022 |
Telomerase-targeting compounds Imetelstat and 6-thio-dG act synergistically with chemotherapy in high-risk neuroblastoma models.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Etoposide; Humans; Mice; Neuroblastoma; Telomerase; Xenograft Model Antitumor Assays | 2022 |
A report on second neo-plasms in seven children with solid tumors.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Humans; Ifosfamide; Infant; Male; Neoplasms, Second Primary; Neuroblastoma; Retrospective Studies; Rhabdomyosarcoma; Vincristine | 2022 |
Digital image analysis workflows for evaluation of cell behavior and tumor microenvironment to aid therapeutic assessment in high-risk neuroblastoma.
Topics: Artificial Intelligence; Etoposide; Humans; Neuroblastoma; Precision Medicine; Tumor Microenvironment; Vitronectin; Workflow | 2023 |
Imidazo-Pyrazole-Loaded Palmitic Acid and Polystyrene-Based Nanoparticles: Synthesis, Characterization and Antiproliferative Activity on Chemo-Resistant Human Neuroblastoma Cells.
Topics: Antineoplastic Agents; Child; Drug Carriers; Etoposide; Humans; Nanoparticles; Neuroblastoma; Palmitic Acid; Polystyrenes; Water | 2023 |
Anti-CCL2 antibody combined with etoposide prolongs survival in a minimal residual disease mouse model of neuroblastoma.
Topics: Animals; Cell Line, Tumor; Chemokine CCL2; Chemokines; Etoposide; Humans; Ligands; Mice; Mice, Inbred NOD; Neoplasm, Residual; Neuroblastoma | 2023 |
Distinct effects of etoposide on glutamine-addicted neuroblastoma.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Etoposide; Glutamine; Glutathione; Humans; Mitochondria; Neuroblastoma; Oxidative Stress; Oxygen Consumption | 2020 |
Enhancing sustained-release local therapy: Single versus dual chemotherapy for the treatment of neuroblastoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Delayed-Action Preparations; Disease Models, Animal; Dose-Response Relationship, Drug; Doxorubicin; Drug Delivery Systems; Etoposide; Humans; Mice; Neoplasm Transplantation; Neuroblastoma; Silk; Tumor Cells, Cultured; Vincristine | 2020 |
Tandem high-dose chemotherapy with autologous stem cell rescue for stage M high-risk neuroblastoma: Experience using melphalan/etoposide/carboplatin and busulfan/melphalan regimens.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Child; Child, Preschool; Dose-Response Relationship, Drug; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Neoplasm Staging; Neuroblastoma; Retrospective Studies; Transplantation, Autologous | 2020 |
Gene Expression Signature of Acquired Chemoresistance in Neuroblastoma Cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Line, Tumor; Cisplatin; Clone Cells; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Neuroblastoma; Nocodazole; Prognosis; Transcriptome; Vincristine | 2020 |
Verteporfin induces apoptosis and reduces the stem cell-like properties in Neuroblastoma tumour-initiating cells through inhibition of the YAP/TAZ pathway.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Drug Repositioning; Etoposide; Humans; Neoplasm Invasiveness; Neoplastic Stem Cells; Neuroblastoma; Side-Population Cells; Signal Transduction; Trans-Activators; Transcription Factors; Transcriptional Coactivator with PDZ-Binding Motif Proteins; Verteporfin; YAP-Signaling Proteins | 2021 |
COVID-19 reinfection in two children with cancer.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Carboplatin; Child, Preschool; Cisplatin; COVID-19; Cyclophosphamide; Daunorubicin; Etoposide; Humans; Male; Neuroblastoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Reinfection; SARS-CoV-2; Vincristine | 2021 |
The inhibition of GHR enhanced cytotoxic effects of etoposide on neuroblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Etoposide; Humans; Mice; Neuroblastoma | 2021 |
C10ORF10/DEPP-mediated ROS accumulation is a critical modulator of FOXO3-induced autophagy.
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Doxorubicin; Etoposide; Extracellular Signal-Regulated MAP Kinases; Forkhead Box Protein O3; Gene Expression; Gene Silencing; Humans; Intracellular Signaling Peptides and Proteins; Models, Biological; Neuroblastoma; Phosphorylation; Proteins; Reactive Oxygen Species; RNA Interference; RNA, Small Interfering; Stress, Physiological | 2017 |
Sphingosine-1-Phosphate Receptor-1 Promotes Environment-Mediated and Acquired Chemoresistance.
Topics: Animals; Apoptosis; Bone Marrow Cells; Drug Resistance, Neoplasm; Etoposide; Fingolimod Hydrochloride; Gene Expression Regulation, Neoplastic; Gene-Environment Interaction; Humans; Mesenchymal Stem Cells; Mice; Neoplasm Recurrence, Local; Neuroblastoma; Receptors, Lysosphingolipid; RNA, Small Interfering; Sphingosine-1-Phosphate Receptors; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2017 |
Thalidomide potentiates etoposide-induced apoptosis in murine neuroblastoma through suppression of NF-κB activation.
Topics: Animals; Apoptosis; Cell Line, Tumor; DNA, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Mice; Neoplasms, Experimental; Neuroblastoma; NF-kappa B; Phosphorylation; Signal Transduction; Thalidomide; Up-Regulation | 2018 |
Neuroblastoma Cell Lines Are Refractory to Genotoxic Drug-Mediated Induction of Ligands for NK Cell-Activating Receptors.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cisplatin; Cytotoxicity, Immunologic; DNA Damage; Etoposide; Humans; Immunotherapy, Adoptive; Irinotecan; Killer Cells, Natural; Neuroblastoma; Reactive Oxygen Species; Topotecan; Tumor Suppressor Protein p53 | 2018 |
P53/PUMA are potential targets that mediate the protection of brain-derived neurotrophic factor (BDNF)/TrkB from etoposide-induced cell death in neuroblastoma (NB).
Topics: Apoptosis; Apoptosis Regulatory Proteins; Brain-Derived Neurotrophic Factor; Cell Death; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Humans; Neuroblastoma; Tumor Suppressor Protein p53 | 2018 |
In vitro and in vivo evaluation of etoposide - silk wafers for neuroblastoma treatment.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bombyx; Cell Line, Tumor; Delayed-Action Preparations; Drug Delivery Systems; Drug Implants; Etoposide; Female; Humans; Mice, Nude; Neuroblastoma; Silk | 2018 |
Resource utilization and toxicities after single versus tandem autologous stem cell rescue in high-risk neuroblastoma using a national administrative database.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Carboplatin; Child; Child, Preschool; Databases, Factual; Etoposide; Female; Follow-Up Studies; Humans; Infant; Infant, Newborn; Length of Stay; Male; Melphalan; Neuroblastoma; Stem Cell Transplantation | 2018 |
Etoposide-resistance in a neuroblastoma model cell line is associated with 13q14.3 mono-allelic deletion and miRNA-15a/16-1 down-regulation.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; N-Myc Proto-Oncogene Protein; Neuroblastoma; Tumor Suppressor Protein p53 | 2018 |
Acute Complications After High-Dose Chemotherapy and Stem-Cell Rescue in Pediatric Patients With High-Risk Neuroblastoma Treated in Countries With Different Resources.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Carboplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Egypt; Etoposide; Female; Humans; Male; Melphalan; Middle Aged; Neuroblastoma; Stem Cell Transplantation; Transplantation Conditioning | 2018 |
Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function.
Topics: Age Factors; Antineoplastic Agents; Area Under Curve; Body Weight; Carboplatin; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Dosage Calculations; Etoposide; Female; Glomerular Filtration Rate; Humans; Infant; Kidney; Male; Melphalan; Models, Biological; Neuroblastoma | 2019 |
Identification of Smac mimetics as novel substrates for p-glycoprotein.
Topics: Apoptosis Regulatory Proteins; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomimetic Materials; Cell Line, Tumor; Dipeptides; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Humans; Indoles; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Mitochondrial Proteins; Neuroblastoma; Oligopeptides; Rhabdomyosarcoma; Thiazoles; Up-Regulation; Vincristine | 2019 |
Extra-Adrenal Adult Neuroblastoma With Aberrant Germ Cell Marker Expression: Maturation After Chemotherapy as an Important Clue to a Challenging Diagnosis.
Topics: Abdominal Neoplasms; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemoradiotherapy; Cyclophosphamide; Dactinomycin; Diagnosis, Differential; Etoposide; Germ Cells; Homeobox Protein Nkx-2.2; Homeodomain Proteins; Humans; Ifosfamide; Inguinal Canal; Male; Neuroblastoma; Nuclear Proteins; Octamer Transcription Factor-3; Transcription Factors; Vincristine | 2019 |
Inhibition of Ubiquitin-Specific Protease 14 Suppresses Cell Proliferation and Synergizes with Chemotherapeutic Agents in Neuroblastoma.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Female; Follow-Up Studies; Gene Knockdown Techniques; HEK293 Cells; Humans; Mice; Mice, Nude; Neuroblastoma; Piperidones; Protein Unfolding; Tumor Burden; Ubiquitin Thiolesterase; Xenograft Model Antitumor Assays | 2019 |
A case series of pediatric oncology patients undergoing successful rapid etoposide desensitization.
Topics: Adolescent; Allergens; Antineoplastic Agents; Child; Clinical Protocols; Cohort Studies; Desensitization, Immunologic; Drug Hypersensitivity; Etoposide; Female; Hodgkin Disease; Humans; Male; Neuroblastoma; Wilms Tumor | 2019 |
Stage 4S Neuroblastoma: A Report of Two Cases Presenting with Extremes of Biological Behavior.
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Humans; Infant; Infant, Newborn; Liver Neoplasms; Male; Neoplasm Staging; Neuroblastoma; Treatment Outcome | 2019 |
[Atypical clinical presentation of a neuroblastoma in an infant].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Constipation; Dexamethasone; Diagnosis, Differential; Etoposide; Female; Follow-Up Studies; Humans; Infant; Inpatients; Kidney Neoplasms; Lumbar Vertebrae; Neoplasm Staging; Neuroblastoma; Paraparesis; Peripheral Nervous System Neoplasms; Phosphopyruvate Hydratase; Radiography; Rectal Prolapse; Spinal Nerve Roots; Treatment Outcome | 2013 |
p38MAPK inhibition: a new combined approach to reduce neuroblastoma resistance under etoposide treatment.
Topics: Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; Neoplasm Proteins; Neoplasm Staging; Nervous System Neoplasms; Neuroblastoma; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction | 2013 |
Critical role of STAT3 in IL-6-mediated drug resistance in human neuroblastoma.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Coculture Techniques; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Melphalan; Membrane Potential, Mitochondrial; Mesenchymal Stem Cells; Monocytes; Neuroblastoma; Receptors, Interleukin-6; STAT3 Transcription Factor; Up-Regulation | 2013 |
TAK1 inhibitor 5Z-7-oxozeaenol sensitizes neuroblastoma to chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Female; Heterografts; Humans; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Neuroblastoma; Signal Transduction; Zearalenone | 2013 |
Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; G2 Phase Cell Cycle Checkpoints; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Neuroblastoma; Panobinostat; Phenylurea Compounds; Protein Kinases; Pyrazines | 2013 |
PAX3 in neuroblastoma: oncogenic potential, chemosensitivity and signalling pathways.
Topics: Antineoplastic Agents, Phytogenic; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Gene Knockdown Techniques; Humans; Neuroblastoma; Oncogenes; Paired Box Transcription Factors; PAX3 Transcription Factor; RNA Interference; RNA, Small Interfering; Signal Transduction; Transcriptome | 2014 |
Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Carboplatin; Child; Child, Preschool; Cisplatin; Computer Simulation; Cyclophosphamide; Disease-Free Survival; Doublecortin Domain Proteins; Doublecortin Protein; Etoposide; Homeodomain Proteins; Humans; Induction Chemotherapy; Infant; Kaplan-Meier Estimate; Microtubule-Associated Proteins; Neuroblastoma; Neuropeptides; Predictive Value of Tests; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Transcription Factors; Tyrosine 3-Monooxygenase; Vincristine | 2014 |
XAV939 inhibits the stemness and migration of neuroblastoma cancer stem cells via repression of tankyrase 1.
Topics: AC133 Antigen; Antigens, CD; Cell Movement; Enzyme Inhibitors; Etoposide; Gene Expression Regulation, Neoplastic; Glycoproteins; Heterocyclic Compounds, 3-Ring; Humans; Neoplastic Stem Cells; Neuroblastoma; Peptides; Tankyrases; Tumor Cells, Cultured | 2014 |
The potential role of pretransplant MIBG diagnostic scintigraphy in targeted administration of 131I-MIBG accompanied by ASCT for high-risk and relapsed neuroblastoma: a pilot study.
Topics: 3-Iodobenzylguanidine; Carboplatin; Child; Child, Preschool; Disease-Free Survival; Etoposide; Female; Humans; Infant; Male; Melphalan; Neoplasm Recurrence, Local; Neuroblastoma; Pilot Projects; Prognosis; Prospective Studies; Radionuclide Imaging; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2014 |
Activity of the polyamine-vectorized anti-cancer drug F14512 against pediatric glioma and neuroblastoma cell lines.
Topics: Animals; Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Cell Survival; Cisplatin; Etoposide; Female; Glioma; Humans; Liver Neoplasms; Melphalan; Mice, Inbred BALB C; Neuroblastoma; Podophyllotoxin; Radiation, Ionizing; Spermine | 2014 |
Radiation therapy to the primary and postinduction chemotherapy MIBG-avid sites in high-risk neuroblastoma.
Topics: 3-Iodobenzylguanidine; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cisplatin; Consolidation Chemotherapy; Cyclophosphamide; Disease-Free Survival; Dose Fractionation, Radiation; Doxorubicin; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Infant; Neoplasm, Residual; Neuroblastoma; Radionuclide Imaging; Radiopharmaceuticals; Retrospective Studies; Survival Rate; Young Adult | 2014 |
C10ORF10/DEPP, a transcriptional target of FOXO3, regulates ROS-sensitivity in human neuroblastoma.
Topics: Apoptosis; beta Catenin; Binding Sites; Brain Neoplasms; Catalase; Etoposide; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; HEK293 Cells; Humans; Hydrogen Peroxide; Intracellular Signaling Peptides and Proteins; Mitochondria; Neuroblastoma; Peroxisomes; Promoter Regions, Genetic; Proteins; Reactive Oxygen Species; RNA, Messenger; Transcription, Genetic | 2014 |
Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Brain Neoplasms; Carboplatin; Child; Child, Preschool; Cisplatin; Cohort Studies; Consolidation Chemotherapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Immunotherapy; Induction Chemotherapy; Infant; Isotretinoin; Male; Neoadjuvant Therapy; Neoplasm Staging; Neuroblastoma; Neurosurgical Procedures; Pilot Projects; Prospective Studies; Radiotherapy; Thiotepa; Topotecan; Treatment Outcome; Vincristine | 2015 |
Fatal hyperammonemia and carbamoyl phosphate synthetase 1 (CPS1) deficiency following high-dose chemotherapy and autologous hematopoietic stem cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Edema; Carbamoyl-Phosphate Synthase (Ammonia); Carbamyl Phosphate; Carboplatin; Child, Preschool; Combined Modality Therapy; Etoposide; Fatal Outcome; Glutamine; Hematopoietic Stem Cell Transplantation; Hep G2 Cells; Humans; Hyperammonemia; Liver; Male; Middle Aged; Neuroblastoma; Ornithine Carbamoyltransferase; Oxidative Phosphorylation | 2015 |
Trk inhibitor attenuates the BDNF/TrkB-induced protection of neuroblastoma cells from etoposide in vitro and in vivo.
Topics: Animals; Apoptosis; Brain-Derived Neurotrophic Factor; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Etoposide; Humans; Membrane Glycoproteins; Mice; Neuroblastoma; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Receptor, trkB | 2015 |
Image-defined risk factor assessment of neurogenic tumors after neoadjuvant chemotherapy is useful for predicting intra-operative risk factors and the completeness of resection.
Topics: Abdominal Neoplasms; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Diagnostic Imaging; Etoposide; Female; Ganglioneuroblastoma; Hematopoietic Stem Cell Transplantation; Humans; Infant; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Neuroblastoma; Postoperative Complications; Risk Assessment; Risk Factors; Thoracic Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Vincristine | 2015 |
TNFα sensitizes neuroblastoma cells to FasL-, cisplatin- and etoposide-induced cell death by NF-κB-mediated expression of Fas.
Topics: Caspase 8; Cell Death; Cell Line, Tumor; Cisplatin; Death Domain Receptor Signaling Adaptor Proteins; Drug Resistance, Neoplasm; Enzyme Activation; Etoposide; Fas Ligand Protein; fas Receptor; Gene Expression Regulation, Neoplastic; Humans; Interferon-gamma; Neuroblastoma; NF-kappa B; Transcription, Genetic; Tumor Necrosis Factor-alpha | 2015 |
The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells.
Topics: Acetylation; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cisplatin; DNA Damage; DNA, Neoplasm; Drug Synergism; Etoposide; Histone Deacetylase Inhibitors; Histones; Humans; Neuroblastoma; Valproic Acid | 2015 |
Erythropoietin protects neuroblastoma cells against etoposide and vincristine by activating ERK and AKT pathways but has no effect in kidney cells.
Topics: Cell Death; Cell Line, Tumor; Cell Proliferation; Erythropoietin; Etoposide; Extracellular Signal-Regulated MAP Kinases; HEK293 Cells; Humans; Kidney; Neuroblastoma; Protective Agents; Proto-Oncogene Proteins c-akt; Receptors, Erythropoietin; Signal Transduction; Vincristine | 2015 |
High mobility group box 1-mediated autophagy promotes neuroblastoma cell chemoresistance.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cell Line, Tumor; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; HMGB1 Protein; Humans; Membrane Proteins; Neuroblastoma; Oxidative Stress | 2015 |
Comparison of toxicity following different conditioning regimens (busulfan/melphalan and carboplatin/etoposide/melphalan) for advanced stage neuroblastoma: Experience of two transplant centers.
Topics: Adolescent; Antineoplastic Agents; Boston; Brain Neoplasms; Busulfan; Carboplatin; Child; Child, Preschool; Egypt; Etoposide; Humans; Infant; Infant, Newborn; Melphalan; Neuroblastoma; Retrospective Studies; Transplantation Conditioning; Treatment Outcome | 2016 |
Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Carboplatin; Child; Child, Preschool; Critical Care; Databases, Factual; Etoposide; Female; Follow-Up Studies; Humans; Incidence; Infant; Length of Stay; Male; Melphalan; Neuroblastoma; Peripheral Blood Stem Cell Transplantation; Sepsis; Stem Cells; Transplantation Conditioning; United States | 2016 |
Detection of Phenotypic Alterations Using High-Content Analysis of Whole-Slide Images.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Child; Cyclophosphamide; Data Interpretation, Statistical; Double-Blind Method; Doxorubicin; Etoposide; Heterografts; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; Mice, Nude; Neoplasm Transplantation; Neuroblastoma | 2016 |
Clinical Significance of Tyrosine Hydroxylase mRNA Transcripts in Peripheral Blood at Diagnosis in Patients with Neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Gene Expression Regulation, Neoplastic; Humans; Infant; Infant, Newborn; Male; Neuroblastoma; Prognosis; Risk Factors; RNA, Messenger; Tyrosine 3-Monooxygenase | 2016 |
Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Child; Child, Preschool; Cohort Studies; Etoposide; Female; Hepatic Veno-Occlusive Disease; Humans; Hypertension, Pulmonary; Infant; Kidney Diseases; Male; Melphalan; Mucositis; Myeloablative Agonists; Neuroblastoma; Pancytopenia; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Young Adult | 2016 |
Glutathione-mediated antioxidant response and aerobic metabolism: two crucial factors involved in determining the multi-drug resistance of high-risk neuroblastoma.
Topics: Acetylcysteine; Antioxidants; Apoptosis; Buthionine Sulfoximine; Catalase; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Cell Survival; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Glutathione; Humans; Hydrogen Peroxide; Lipid Peroxidation; Neuroblastoma; Topoisomerase II Inhibitors; Up-Regulation | 2016 |
Low dose of arsenic trioxide inhibits multidrug resistant-related P-glycoprotein expression in human neuroblastoma cell line.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; G2 Phase Cell Cycle Checkpoints; Humans; Neuroblastoma; Oxides | 2016 |
Wip1 inhibitor GSK2830371 inhibits neuroblastoma growth by inducing Chk2/p53-mediated apoptosis.
Topics: Aminopyridines; Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 2; Dipeptides; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Mice; Neuroblastoma; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2016 |
Pelvic teratoma with extensive spinal involvement in a neonate: an important differential diagnosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Diagnosis, Differential; Etoposide; Female; Humans; Hypertension; Infant; Neoplasm, Residual; Neuroblastoma; Pelvic Neoplasms; Retroperitoneal Neoplasms; Spinal Cord Compression; Teratoma; Treatment Outcome | 2008 |
Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Infant; Male; Neuroblastoma; Paclitaxel; Survival Rate; Topotecan; Transplantation Conditioning; Treatment Outcome; Vincristine; Young Adult | 2008 |
Inhibition of Thr-55 phosphorylation restores p53 nuclear localization and sensitizes cancer cells to DNA damage.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Apigenin; Cell Line, Tumor; Cell Nucleus; Cytoplasm; DNA Damage; Etoposide; Exportin 1 Protein; Humans; Karyopherins; Models, Biological; Neuroblastoma; Phosphorylation; Proto-Oncogene Proteins c-mdm2; Receptors, Cytoplasmic and Nuclear; Threonine; Tumor Suppressor Protein p53 | 2008 |
Prognostic significance of circulating tumor cells and bone marrow micrometastasis in advanced neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Neoplasms; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Genes, myc; Hematopoietic Stem Cell Transplantation; Humans; Infant; Kaplan-Meier Estimate; Male; Neoplasm Staging; Neoplastic Cells, Circulating; Neuroblastoma; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Vincristine | 2008 |
Hepatoblastoma presenting with focal nodular hyperplasia after treatment of neuroblastoma.
Topics: Adrenal Gland Neoplasms; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Fluorouracil; Focal Nodular Hyperplasia; Granulocyte Colony-Stimulating Factor; Hepatectomy; Hepatoblastoma; Humans; Ifosfamide; Immunoglobulin G; Incidental Findings; Liver Neoplasms; Male; Melphalan; Mesna; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Neuroblastoma; Radiotherapy, Adjuvant; Tomography, X-Ray Computed; Vincristine | 2008 |
Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia; Male; Myelodysplastic Syndromes; Neuroblastoma; Prospective Studies; Remission Induction; Risk Reduction Behavior; Topoisomerase II Inhibitors; Vincristine; Young Adult | 2009 |
Repression of BIRC5/survivin by FOXO3/FKHRL1 sensitizes human neuroblastoma cells to DNA damage-induced apoptosis.
Topics: Alleles; Apoptosis; Cell Line, Tumor; DNA Damage; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Mitochondria; Neuroblastoma; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Small Interfering; Survivin; Transgenes | 2009 |
Fenretinide-induced caspase-8 activation and apoptosis in an established model of metastatic neuroblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Bone Marrow; Caspase 8; Caspase Inhibitors; Cell Line, Tumor; Cell Survival; Cysteine Proteinase Inhibitors; Drug Resistance, Neoplasm; Enzyme Activation; Etoposide; Fenretinide; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Neuroblastoma; Reverse Transcriptase Polymerase Chain Reaction; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays | 2009 |
Etoposide induces protein kinase Cdelta- and caspase-3-dependent apoptosis in neuroblastoma cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Etoposide; Humans; Neuroblastoma; Protein Kinase C-delta | 2009 |
A focal lesion in the falx cerebri: Harbinger of classic stage 4 neuroblastoma in an infant cured despite residual disease after minimal therapy.
Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Dura Mater; Etoposide; Femur; Humans; Infant; Iodine Radioisotopes; Male; Meningeal Neoplasms; Neoplasm Staging; Neoplasm, Residual; Neuroblastoma; Radionuclide Imaging; Remission Induction; Skin Neoplasms | 2009 |
Neuroblastoma in the newborn. A study of the Italian Neuroblastoma Registry.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Gene Amplification; Humans; Infant; Infant, Newborn; Italy; Male; Neoplasm Staging; Neuroblastoma; Pregnancy; Prenatal Diagnosis; Registries; Survival Rate; Treatment Outcome; Vincristine | 2009 |
Neuroblastoma involvement of the falx cerebri.
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Lineage; Cyclophosphamide; Doxorubicin; Dura Mater; Etoposide; Female; Humans; Infant; Infant, Newborn; Male; Meningeal Neoplasms; Microphthalmia-Associated Transcription Factor; Neoplasm Staging; Neural Crest; Neuroblastoma; Pulmonary Veins; Remission Induction; Skin Neoplasms; Waardenburg Syndrome | 2009 |
Advanced adult esthesioneuroblastoma successfully treated with cisplatin and etoposide alternated with doxorubicin, ifosfamide and vincristine.
Topics: Adult; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Doxorubicin; Endocrine Gland Neoplasms; Etoposide; Humans; Ifosfamide; Magnetic Resonance Imaging; Male; Neuroblastoma; Tomography, X-Ray Computed; Vincristine | 2010 |
[Curative effects of the protocol of CDV combined with CiE as pre-operative chemotherapy in high-risk childhood neuroblastoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Cyclophosphamide; Dacarbazine; Etoposide; Female; Humans; Infant; Male; Neuroblastoma; Retrospective Studies; Vincristine | 2009 |
Hypoxia promotes etoposide (VP-16) resistance in neuroblastoma CHP126 cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Cycle; Cell Hypoxia; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Etoposide; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Genes, p53; Humans; Indicators and Reagents; Neoplasm Proteins; Neuroblastoma; Signal Transduction | 2010 |
Renal impairment due to white-cell lysis after G-CSF and chemotherapy during pediatric autologous stem cell transplantation.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Combined Modality Therapy; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Male; Melphalan; Neuroblastoma; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome; Tumor Lysis Syndrome | 2010 |
Topotecan and etoposide combination to test neuroblastoma in pediatric preclinical testing program.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Child; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Evaluation, Preclinical; Etoposide; Humans; Neuroblastoma; Topotecan | 2010 |
Resistance to chemotherapeutic agents and promotion of transforming activity mediated by embryonic stem cell-expressed Ras (ERas) signal in neuroblastoma cells.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Neuroblastoma; Oncogene Protein p21(ras); Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Time Factors; Transfection; Vinblastine | 2010 |
Chromatin remodelling at the topoisomerase II-beta promoter is associated with enhanced sensitivity to etoposide in human neuroblastoma cell lines.
Topics: Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Line, Tumor; Cell Survival; Chromatin Assembly and Disassembly; Chromatin Immunoprecipitation; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Synergism; Epigenomics; Etoposide; Histone Deacetylase Inhibitors; Humans; Inhibitory Concentration 50; Neuroblastoma; Valproic Acid | 2010 |
Targeting gastrin-releasing peptide as a new approach to treat aggressive refractory neuroblastomas.
Topics: Apoptosis; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Etoposide; Gastrin-Releasing Peptide; Humans; Neuroblastoma; Poly(ADP-ribose) Polymerases; RNA, Small Interfering; Transfection; Tumor Suppressor Protein p53; Vincristine | 2011 |
Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma.
Topics: Abdominal Neoplasms; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Etoposide; Female; Humans; Ifosfamide; Infant; Kaplan-Meier Estimate; Lomustine; Male; Melphalan; Mesna; Neuroblastoma; Pilot Projects; Risk Factors; Thoracic Neoplasms; Topotecan; Treatment Outcome | 2011 |
Antagonism of cytotoxic chemotherapy in neuroblastoma cell lines by 13-cis-retinoic acid is mediated by the antiapoptotic Bcl-2 family proteins.
Topics: Alkylating Agents; Apoptosis; Biphenyl Compounds; Cell Line, Tumor; Cisplatin; Cytochromes c; Cytoprotection; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Isotretinoin; Melphalan; Membrane Potential, Mitochondrial; Mitochondria; Neuroblastoma; Nitrophenols; Piperazines; Protective Agents; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Signal Transduction; Sulfonamides; Topoisomerase Inhibitors; Tumor Suppressor Protein p53 | 2010 |
Infratentorial brain metastases of pediatric non-epithelial malignant tumors: three case reports.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Dactinomycin; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant; Infratentorial Neoplasms; Irinotecan; Melphalan; Neoplasm Metastasis; Neuroblastoma; Rhabdomyosarcoma; Thiotepa; Topotecan; Vincristine | 2011 |
Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cisplatin; Cyclophosphamide; Etoposide; Female; Gene Amplification; Humans; Infant; Male; N-Myc Proto-Oncogene Protein; Necrosis; Neoplasm Staging; Neuroblastoma; Nuclear Proteins; Oncogene Proteins; Pilot Projects; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome; Vincristine | 2011 |
Neuroblastoma in an adult: case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Brain Neoplasms; Carboplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Mesna; Neuroblastoma; Spinal Cord Compression; Spinal Cord Neoplasms; Thoracic Vertebrae; Vincristine; Young Adult | 2010 |
PKCδ sensitizes neuroblastoma cells to L-buthionine-sulfoximine and etoposide inducing reactive oxygen species overproduction and DNA damage.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Buthionine Sulfoximine; DNA Damage; Enzyme Activation; Enzyme Inhibitors; Etoposide; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Neuroblastoma; Onium Compounds; Protein Kinase C-delta; Reactive Oxygen Species; RNA, Small Interfering; Transfection; Tumor Cells, Cultured | 2011 |
Treatment of advanced neuroblastoma in children over 1 year of age: the critical role of ¹³¹I-metaiodobenzylguanidine combined with chemotherapy in a rapid induction regimen.
Topics: 3-Iodobenzylguanidine; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Humans; Infant; Iodine Radioisotopes; Male; Neuroblastoma; Pilot Projects; Radiopharmaceuticals; Remission Induction; Survival Rate; Treatment Outcome; Vincristine | 2011 |
Amyloid precursor protein binding protein Fe65 is cleaved by caspases during DNA damage-induced apoptosis.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Apoptosis; Camptothecin; Caspases; Cell Line, Tumor; Cytotoxins; DNA Damage; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Humans; Nerve Tissue Proteins; Neuroblastoma; Neurons; Nuclear Proteins; Signal Transduction | 2011 |
Perifosine-induced inhibition of Akt attenuates brain-derived neurotrophic factor/TrkB-induced chemoresistance in neuroblastoma in vivo.
Topics: Brain Neoplasms; Brain-Derived Neurotrophic Factor; Cell Line, Tumor; Drug Resistance, Neoplasm; Etoposide; Humans; Neuroblastoma; Phosphorylation; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Receptor, trkB; Tetracycline | 2011 |
[Mobilization and collection of autologous peripheral blood stem cells by CIE or IEV protocol in children with malignant solid tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Epirubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Male; Neuroblastoma; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Rhabdomyosarcoma; Transplantation, Autologous | 2011 |
Reciprocal potentiation of the antitumoral activities of FK866, an inhibitor of nicotinamide phosphoribosyltransferase, and etoposide or cisplatin in neuroblastoma cells.
Topics: Acrylamides; Adenosine; Adenosine Triphosphate; Annexin A5; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Autophagy; Autophagy-Related Protein 7; Cell Death; Cell Line, Tumor; Cell Nucleus; Cell Survival; Chloroquine; Cisplatin; Comet Assay; DNA Damage; Down-Regulation; Drug Synergism; Etoposide; Humans; Immunohistochemistry; L-Lactate Dehydrogenase; Neuroblastoma; Nicotinamide Phosphoribosyltransferase; Piperidines; Ubiquitin-Activating Enzymes | 2011 |
Protein kinase C stabilizes X-linked inhibitor of apoptosis protein (XIAP) through phosphorylation at Ser(87) to suppress apoptotic cell death.
Topics: Alzheimer Disease; Antineoplastic Agents, Phytogenic; Apoptosis; Brain; Cell Death; Cell Line, Tumor; Etoposide; Humans; Neuroblastoma; Neurons; Phosphorylation; Protein Kinase C; Serine; Tetradecanoylphorbol Acetate; Transfection; X-Linked Inhibitor of Apoptosis Protein | 2011 |
Combination of IFNγ and chemotherapeutic agents increase TRAIL sensitivity of neuroblastoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Caspase 8; Cell Line, Tumor; Doxorubicin; Etoposide; Humans; Interferon-gamma; Neuroblastoma; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Messenger; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation | 2011 |
DNA-damaging drug-induced apoptosis sensitized by N-myc in neuroblastoma cells.
Topics: Antineoplastic Agents; Apoptosis; Caspase 9; Cell Line, Tumor; Child; DNA Fragmentation; DNA, Neoplasm; Doxorubicin; Etoposide; Gene Expression Regulation, Neoplastic; Genetic Vectors; Humans; Neuroblastoma; Proto-Oncogene Proteins c-myc; Retroviridae; Signal Transduction; Tumor Suppressor Protein p53 | 2012 |
Application of high-dose rate (60)Co remote after-loading system for local recurrent neuroblastoma.
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Busulfan; Carboplatin; Cisplatin; Cobalt Radioisotopes; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant; Male; Melphalan; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neuroblastoma; Peripheral Blood Stem Cell Transplantation; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Vidarabine; Vincristine | 2011 |
Dual inhibition of MAGL and type II topoisomerase by N-phenylmaleimides as a potential strategy to reduce neuroblastoma cell growth.
Topics: Antineoplastic Agents; Arachidonic Acids; Benzodioxoles; Cannabinoid Receptor Modulators; Carbamates; Cell Proliferation; DNA Topoisomerases, Type II; Endocannabinoids; Etoposide; Glycerides; Humans; Maleimides; Monoacylglycerol Lipases; Neuroblastoma; Oxadiazoles; Piperidines; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2012 |
Resistance of neuroblastoma GI-ME-N cell line to glutathione depletion involves Nrf2 and heme oxygenase-1.
Topics: Antineoplastic Agents, Phytogenic; Buthionine Sulfoximine; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Etoposide; Gene Expression; Gene Knockdown Techniques; Glutamate-Cysteine Ligase; Glutathione; Heme Oxygenase-1; Humans; Neuroblastoma; NF-E2-Related Factor 2; Oxidative Stress; Protoporphyrins; Reactive Nitrogen Species; Reactive Oxygen Species | 2012 |
FOXO3-induced reactive oxygen species are regulated by BCL2L11 (Bim) and SESN3.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Doxorubicin; Etoposide; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Knockdown Techniques; Heat-Shock Proteins; Humans; Membrane Proteins; Mitochondria; Neuroblastoma; Neurons; Proto-Oncogene Proteins; Reactive Oxygen Species; Recombinant Fusion Proteins; Tetracycline | 2012 |
Combination of an allosteric Akt Inhibitor MK-2206 with etoposide or rapamycin enhances the antitumor growth effect in neuroblastoma.
Topics: Allosteric Regulation; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Etoposide; Female; Heterocyclic Compounds, 3-Ring; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Neuroblastoma; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Sirolimus; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Functional switching of ATM: sensor of DNA damage in proliferating cells and mediator of Akt survival signal in post-mitotic human neuron-like cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Ataxia Telangiectasia; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Cell Cycle Proteins; Cell Differentiation; Cell Line, Tumor; DNA Damage; DNA-Binding Proteins; Etoposide; Histones; Humans; Morpholines; Neuroblastoma; Neurons; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Pyrones; Signal Transduction; Topoisomerase Inhibitors; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2012 |
MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; Disease Models, Animal; Disease-Free Survival; Down-Regulation; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Membrane Glycoproteins; Mice; Mice, Inbred Strains; Mice, SCID; MicroRNAs; Neuroblastoma; Predictive Value of Tests; Proportional Hazards Models; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Real-Time Polymerase Chain Reaction; Receptor, trkB; Reverse Transcriptase Polymerase Chain Reaction; Up-Regulation | 2012 |
Over-expression of HSP70 attenuates caspase-dependent and caspase-independent pathways and inhibits neuronal apoptosis.
Topics: Amyloid beta-Peptides; Animals; Apoptosis; Apoptosis Regulatory Proteins; Caspases; Cells, Cultured; Cerebral Cortex; Embryo, Mammalian; Etoposide; Gene Expression Regulation; Green Fluorescent Proteins; HSP70 Heat-Shock Proteins; Humans; Immunoprecipitation; Neural Inhibition; Neuroblastoma; Neurons; Peptide Fragments; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Protein Binding; Rats; Signal Transduction; Sphingosine; Staurosporine; Transfection | 2012 |
5-day/5-drug myeloablative outpatient regimen for resistant neuroblastoma.
Topics: 3-Iodobenzylguanidine; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Irinotecan; Male; Neuroblastoma; Outpatients; Radionuclide Imaging; Radiopharmaceuticals; Retrospective Studies; Salvage Therapy; Temozolomide | 2013 |
Pharmacological inhibition of GSK3 attenuates DNA damage-induced apoptosis via reduction of p53 mitochondrial translocation and Bax oligomerization in neuroblastoma SH-SY5Y cells.
Topics: Antibiotics, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; bcl-Associated Death Protein; Camptothecin; Caspase 3; Cell Line, Tumor; Cytochromes c; DNA Damage; Doxorubicin; Etoposide; Gene Expression Regulation; Glycogen Synthase Kinase 3; Humans; Mitochondria; Neuroblastoma; Poly(ADP-ribose) Polymerases; Protein Multimerization; Protein Transport; Signal Transduction; Tumor Suppressor Protein p53 | 2013 |
Impact of histone deacetylase inhibitor valproic acid on the anticancer effect of etoposide on neuroblastoma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bone Marrow Neoplasms; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Histone Deacetylase Inhibitors; Humans; Neuroblastoma; Risk Factors; Valproic Acid | 2012 |
The translocator protein (TSPO) ligand PK11195 induces apoptosis and cell cycle arrest and sensitizes to chemotherapy treatment in pre- and post-relapse neuroblastoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP-Binding Cassette Transporters; Carboplatin; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Etoposide; Humans; Isoquinolines; Ligands; Melphalan; Neuroblastoma; Receptors, GABA; Recurrence; RNA, Messenger | 2013 |
Role of GST P1-1 in mediating the effect of etoposide on human neuroblastoma cell line Sh-Sy5y.
Topics: Apoptosis; Blotting, Western; Clone Cells; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Enzymologic; Glutathione; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Isoenzymes; Neuroblastoma; Oxidative Stress; Tumor Cells, Cultured | 2002 |
Anti-tumor promoting effects of palmitoyl: protein thioesterase inhibitors against a human neurotumor cell line.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Doxorubicin; Enzyme Inhibitors; Etoposide; Humans; Neuroblastoma; Thiolester Hydrolases; Tumor Cells, Cultured | 2002 |
Resistance to chemotherapy mediated by TrkB in neuroblastomas.
Topics: Antibodies; Apoptosis; Brain-Derived Neurotrophic Factor; Cisplatin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Neuroblastoma; Protein-Tyrosine Kinases; Receptor, trkB; Transfection; Tumor Cells, Cultured | 2002 |
Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3'-kinase pathway.
Topics: Animals; Apoptosis; Brain-Derived Neurotrophic Factor; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Activation; Etoposide; Humans; Neuroblastoma; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Promoter Regions, Genetic; Rats; Receptor, trkB; Signal Transduction; Tetracycline; Transfection; Tumor Cells, Cultured; Vinblastine | 2002 |
Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cisplatin; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Gene Amplification; Genes, myc; Hematopoietic Stem Cell Transplantation; Humans; Infant; Japan; Life Tables; Male; Neuroblastoma; Prognosis; Prospective Studies; Remission Induction; Survival Rate; Transplantation Conditioning; Treatment Outcome | 2002 |
p53 mediates DNA damaging drug-induced apoptosis through a caspase-9-dependent pathway in SH-SY5Y neuroblastoma cells.
Topics: Apoptosis; Caspase 9; Caspases; Cell Nucleus; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cytochrome c Group; DNA Damage; DNA Fragmentation; Dose-Response Relationship, Drug; Doxorubicin; Enzyme Activation; Etoposide; Genes, p53; Humans; Immunoblotting; Microscopy, Fluorescence; Mitochondria; Neuroblastoma; Signal Transduction; Time Factors; Transcription, Genetic; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy.
Topics: 3-Iodobenzylguanidine; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Catecholamines; Child; Child, Preschool; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Infant; Male; Neuroblastoma; Radionuclide Imaging; Radiopharmaceuticals; Remission Induction; Risk | 2003 |
Neuroblastoma directed therapy by a rational prodrug design of etoposide as a substrate for tyrosine hydroxylase.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Blotting, Western; Cell Survival; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Drug Design; Escherichia coli; Etoposide; Humans; Mice; Neuroblastoma; Plasmids; Prodrugs; Substrate Specificity; Tumor Cells, Cultured; Tyrosine; Tyrosine 3-Monooxygenase | 2003 |
Rationally designed hydrolytically activated etoposide prodrugs, a novel strategy for the treatment of neuroblastoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Cell Survival; DNA Primers; Drug Design; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Hydrolysis; Maximum Tolerated Dose; Mice; Neuroblastoma; Plasmids; Prodrugs; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured | 2003 |
Treatment of stage 4s neuroblastoma--report of 10 years' experience of the French Society of Paediatric Oncology (SFOP).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Etoposide; Female; France; Genetic Markers; Humans; Infant; Infant, Newborn; Male; Neuroblastoma; Patient Care Planning; Prognosis; Retrospective Studies; Societies, Medical; Vincristine | 2003 |
Transduction of green fluorescent protein increased oxidative stress and enhanced sensitivity to cytotoxic drugs in neuroblastoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; B7-1 Antigen; Buthionine Sulfoximine; Carboplatin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Glutathione; Green Fluorescent Proteins; Humans; Lentivirus; Luminescent Proteins; Melphalan; Mutation; Neuroblastoma; Oxidative Stress; Transduction, Genetic; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2003 |
Pneumocystis carinii pneumonia: a late presentation following treatment for stage IV neuroblastoma.
Topics: Abdominal Neoplasms; Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Fatal Outcome; Female; Humans; Immunocompromised Host; Isotretinoin; Neoplasm Staging; Neuroblastoma; Opportunistic Infections; Pneumonia, Pneumocystis; Radiotherapy, Adjuvant; Trimethoprim, Sulfamethoxazole Drug Combination; Vincristine | 2003 |
[Evaluation of efficacy of treatment for 30 children with neuroblastoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Infant; Male; Neoplasm Staging; Neuroblastoma; Retrospective Studies; Teniposide; Treatment Outcome; Vincristine | 2003 |
Arsenic trioxide-induced death of neuroblastoma cells involves activation of Bax and does not require p53.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Blotting, Western; Calpain; Carboplatin; Caspase 3; Caspases; Cell Line, Tumor; Cytochromes c; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Mutation; Neuroblastoma; Oxides; Proto-Oncogene Proteins c-bcl-2; Time Factors; Tumor Suppressor Protein p53; Vincristine | 2004 |
Predicting resistance or response to chemotherapy by proton magnetic resonance spectroscopy in neuroblastoma.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Choline; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Hydrocarbons; Irinotecan; Magnetic Resonance Spectroscopy; Matched-Pair Analysis; Methane; Neuroblastoma; Predictive Value of Tests; Protons; Rats; Rats, Nude; Reproducibility of Results; Transplantation, Heterologous | 2004 |
[A case of retroperitoneal neuroblastoma in an adult with extensive bone marrow metastasis].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Carboplatin; Dactinomycin; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Male; Neuroblastoma; Paraplegia; Retroperitoneal Neoplasms; Skull Neoplasms; Vincristine | 2004 |
A proteomic investigation into etoposide chemo-resistance of neuroblastoma cell lines.
Topics: Antineoplastic Agents, Phytogenic; Brain Neoplasms; Cell Death; DNA Fragmentation; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Etoposide; Humans; Mass Spectrometry; Neuroblastoma; Proteome; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2005 |
Pancratistatin: a natural anti-cancer compound that targets mitochondria specifically in cancer cells to induce apoptosis.
Topics: Amaryllidaceae Alkaloids; Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 3; Caspases; Cells, Cultured; Etoposide; Fibroblasts; Humans; Intracellular Membranes; Isoquinolines; Mitochondria; Neuroblastoma; Paclitaxel; Permeability; Proteasome Endopeptidase Complex; Reactive Oxygen Species; Tumor Cells, Cultured | 2005 |
Role of heat treatment in childhood cancers: distinct resistance profiles of solid tumor cell lines towards combined thermochemotherapy.
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Division; Cell Line, Tumor; Cell Survival; Child; Cisplatin; Combined Modality Therapy; Cross-Linking Reagents; Etoposide; Humans; Hyperthermia, Induced; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Topoisomerase II Inhibitors | 2005 |
Reversible dilated cardiomyopathy and neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cardiomyopathy, Dilated; Etoposide; Female; Humans; Infant; Kidney Neoplasms; Neuroblastoma | 2005 |
High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy.
Topics: Adolescent; Adult; Animals; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody Formation; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin G; Immunosuppressive Agents; Immunotherapy; Infant; Male; Melphalan; Mice; Neuroblastoma; Retrospective Studies; Thiotepa; Topotecan; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine; Whole-Body Irradiation | 2007 |
Role of chemotherapy resistance genes in outcome of neuroblastoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Cell Line, Tumor; Child; Child, Preschool; Chromosome Deletion; Chromosomes, Human, Pair 1; Cisplatin; Computer Systems; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression Profiling; Genes, MDR; Genes, myc; Humans; Infant; Kaplan-Meier Estimate; Male; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neuroblastoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; S Phase; Treatment Outcome; Vault Ribonucleoprotein Particles; Vincristine | 2007 |
Downregulation of Bim by brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from paclitaxel but not etoposide or cisplatin-induced cell death.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Brain-Derived Neurotrophic Factor; Cell Death; Cisplatin; Down-Regulation; Enzyme Activation; Etoposide; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Membrane Proteins; Mitogen-Activated Protein Kinases; Molecular Mimicry; Neuroblastoma; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Isoforms; Proto-Oncogene Proteins; Receptor, trkB; RNA, Messenger; RNA, Small Interfering | 2007 |
Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapy.
Topics: Animals; Camptothecin; Carboxylesterase; Catalysis; Cell Division; Etoposide; Humans; Inhibitory Concentration 50; Irinotecan; Molecular Structure; Neuroblastoma; Prodrugs; Rabbits; Tumor Cells, Cultured | 2006 |
Survivin inhibits apoptosis induced by TRAIL, and the ratio between survivin and TRAIL receptors is predictive of recurrent disease in neuroblastoma.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Child; Etoposide; Ganglioneuroblastoma; Ganglioneuroma; GPI-Linked Proteins; Humans; Inhibitor of Apoptosis Proteins; Membrane Glycoproteins; Microtubule-Associated Proteins; Neoplasm Proteins; Neoplasm Recurrence, Local; Neuroblastoma; Predictive Value of Tests; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Member 10c; Survivin; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor Decoy Receptors; Tumor Necrosis Factor-alpha | 2006 |
A novel pattern of transaminase elevation associated with autologous transplant for neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child, Preschool; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Liver Function Tests; Male; Neuroblastoma; Retrospective Studies; Risk Factors; Transaminases; Transplantation Conditioning; Transplantation, Autologous | 2006 |
Chronic hypoxia promotes hypoxia-inducible factor-1alpha-dependent resistance to etoposide and vincristine in neuroblastoma cells.
Topics: Apoptosis; Cell Hypoxia; Cell Line, Tumor; Cisplatin; Down-Regulation; Drug Resistance, Neoplasm; Etoposide; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Neuroblastoma; Proto-Oncogene Proteins c-bcl-2; Vincristine | 2006 |
Stage 4S neuroblastoma, a disseminated tumor with excellent outcome.
Topics: Adrenal Gland Neoplasms; Adrenal Glands; Age Factors; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hepatomegaly; Humans; Infant; Infant, Newborn; Liver Neoplasms; Male; Neoplasm Regression, Spontaneous; Neoplasm Staging; Neuroblastoma; Prognosis; Retrospective Studies; Saudi Arabia; Skin; Skin Neoplasms; Survival Analysis; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Vincristine | 2006 |
Signaling from p53 to NF-kappaB determines the chemotherapy responsiveness of neuroblastoma.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Doxorubicin; Etoposide; Humans; MAP Kinase Kinase 1; Mutation; Neuroblastoma; NF-kappa B; Prognosis; Ribosomal Protein S6 Kinases, 90-kDa; Signal Transduction; Tumor Suppressor Protein p53 | 2006 |
Iodine-131-metaiodobenzylguanidine therapy with reduced-intensity allogeneic stem cell transplantation in recurrent neuroblastoma.
Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Camptothecin; Child, Preschool; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Doxorubicin; Etoposide; Fatal Outcome; Female; Humans; Iodine Radioisotopes; Irinotecan; Neuroblastoma; Recurrence; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vincristine | 2008 |
[Neuroblastoma trial to overcome a rare malignant disease].
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Neuroblastoma; Rare Diseases; Transplantation, Autologous | 2007 |
Purging of the neuroblastoma stem cell compartment and tumor regression on exposure to hypoxia or cytotoxic treatment.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Clone Cells; Electrophysiology; Etoposide; Humans; Hypoxia; Immunohistochemistry; Neoplastic Stem Cells; Neuroblastoma | 2007 |
Combination of gamma-interferon with TRAIL and cisplatin or etoposide induces apoptosis in human neuroblastoma cell line SH-SY5Y.
Topics: Antineoplastic Agents; Apoptosis; Caspase 8; Cell Line, Tumor; Cell Survival; Cisplatin; Etoposide; Humans; Interferon-gamma; Neuroblastoma; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; TNF-Related Apoptosis-Inducing Ligand | 2007 |
O(2/3) exposure inhibits cell progression affecting cyclin B1/cdk1 activity in SK-N-SH while induces apoptosis in SK-N-DZ neuroblastoma cells.
Topics: Antineoplastic Agents; Apoptosis; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclin B; Cyclin B1; Cytoplasm; Deoxycytidine; Etoposide; Gemcitabine; Humans; Neuroblastoma; Oxygen; Ozone; Reactive Oxygen Species | 2007 |
Inhibitory effect of polyunsaturated fatty acids on apoptosis induced by etoposide, okadaic acid and AraC in Neuro2a cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Fatty Acids, Unsaturated; Mice; Neuroblastoma; Neurons; Okadaic Acid | 2007 |
Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide.
Topics: Acetylation; Antineoplastic Agents; Cell Line, Tumor; Depsipeptides; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Gene Expression; Gene Expression Profiling; Genes, Neoplasm; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Neuroblastoma; Oligonucleotide Array Sequence Analysis; RNA, Messenger; RNA, Small Interfering | 2007 |
The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Line, Tumor; Cell Survival; Dipeptides; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Immunoenzyme Techniques; Male; Melphalan; Mice; Molecular Structure; Neovascularization, Pathologic; Neuroblastoma; Prodrugs; Rats; Rats, Nude; Tumor Cells, Cultured; Vincristine | 2007 |
Neoadjuvant bleomycin, etoposide, and cisplatin in adult neuroblastoma arising from the broad ligament of the uterus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Broad Ligament; Cisplatin; Etoposide; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neuroblastoma; Tomography, X-Ray Computed; Treatment Outcome; Uterine Neoplasms | 2007 |
Inactivation of glycogen synthase kinase-3beta contributes to brain-derived neutrophic factor/TrkB-induced resistance to chemotherapy in neuroblastoma cells.
Topics: Antineoplastic Agents; Brain-Derived Neurotrophic Factor; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Flow Cytometry; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Membrane Potentials; Neuroblastoma; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptor, trkB; RNA, Small Interfering | 2007 |
Prospective tracing of MLL-FRYL clone with low MEIS1 expression from emergence during neuroblastoma treatment to diagnosis of myelodysplastic syndrome.
Topics: Alkylating Agents; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child, Preschool; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 4; Combined Modality Therapy; DNA Topoisomerases, Type II; Drosophila melanogaster; Etoposide; Gene Expression Regulation, Neoplastic; Granulocyte-Macrophage Colony-Stimulating Factor; Histone-Lysine N-Methyltransferase; Homeodomain Proteins; Humans; Male; Myelodysplastic Syndromes; Myeloid Ecotropic Viral Integration Site 1 Protein; Myeloid-Lymphoid Leukemia Protein; Neoplasm Proteins; Neuroblastoma; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Sequence Homology, Amino Acid; Topoisomerase II Inhibitors; Translocation, Genetic; Transplantation, Autologous | 2008 |
Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cyclophosphamide; Cytoprotection; Etoposide; Fasting; Female; Glioma; Glucose; Humans; Mice; Mice, Inbred Strains; Neuroblastoma; Oxidative Stress; Proto-Oncogene Mas; Rats; Reactive Oxygen Species; Saccharomyces cerevisiae | 2008 |
Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age.
Topics: Abdominal Neoplasms; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Infections; Male; Neoplasm Staging; Neuroblastoma; Platelet Transfusion; Remission Induction; Retrospective Studies; Thoracic Neoplasms; Vincristine | 1994 |
Exposure and schedule dependency of etoposide in neuroblastoma and leukaemia cells in vitro.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Survival; Culture Media; Dose-Response Relationship, Drug; Drug Stability; Etoposide; Humans; Leukemia L1210; Neuroblastoma; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1995 |
[A case of sacral neuroblastoma in an adult successfully treated with combination chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Neuroblastoma; Sacrum; Spinal Neoplasms | 1995 |
Phenoxyl radicals of etoposide (VP-16) can directly oxidize intracellular thiols: protective versus damaging effects of phenolic antioxidants.
Topics: Animals; Antioxidants; CHO Cells; Chromans; Chromatography, High Pressure Liquid; Cricetinae; DNA, Single-Stranded; Drug Interactions; Etoposide; Free Radical Scavengers; Humans; Luminescent Measurements; Neuroblastoma; Oxidation-Reduction; Sulfhydryl Compounds; Tumor Cells, Cultured | 1995 |
Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Cell Line; Cell Survival; Cisplatin; Cyclophosphamide; DNA Damage; DNA, Neoplasm; Etoposide; Flow Cytometry; Humans; Multigene Family; Neuroblastoma; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Time Factors; Transfection; Tumor Cells, Cultured | 1995 |
Ifosfamide: should the honeymoon be over?
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Child; Cisplatin; Cyclophosphamide; Drug Administration Schedule; Drug Tolerance; Etoposide; Female; Humans; Ifosfamide; Kidney; Neuroblastoma; Time Factors | 1995 |
21-day schedule oral etoposide in children--a feasibility study.
Topics: Administration, Oral; Adolescent; Child; Child, Preschool; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Humans; Leukemia; Leukopenia; Male; Neuroblastoma; Neutropenia; Sarcoma; Thrombocytopenia; Treatment Outcome | 1993 |
Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival.
Topics: Animals; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; Enzyme-Linked Immunosorbent Assay; Etoposide; Gangliosides; Humans; Melphalan; Mice; Neoplasm Staging; Neuroblastoma; Prognosis; Radiotherapy Dosage; Survival Analysis; Survival Rate; Thiotepa | 1994 |
Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma.
Topics: Apoptosis; Cell Division; Cell Survival; Cisplatin; DNA, Neoplasm; Drug Resistance; Etoposide; Flow Cytometry; Gene Expression; Humans; Neuroblastoma; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 1994 |
Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation.
Topics: Adolescent; Brain Neoplasms; Child; Child, Preschool; Etoposide; Female; Humans; Infant; Male; Metabolic Clearance Rate; Neoplasms; Neuroblastoma; Pineal Gland; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sarcoma; Soft Tissue Neoplasms; Teratoma | 1993 |
Escalating dose of continuous infusion combination chemotherapy for refractory neuroblastoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Doxorubicin; Etoposide; Humans; Infant; Infusions, Intravenous; Neuroblastoma; Survival Rate | 1993 |
[Combination chemotherapy of ifosfamide and etoposide for advanced neuroblastoma].
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Infant; Neuroblastoma; Retroperitoneal Neoplasms | 1995 |
Metastatic neuroblastoma in children older than one year: prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring system.
Topics: 3-Iodobenzylguanidine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Brain Neoplasms; Carboplatin; Child, Preschool; Cisplatin; Etoposide; Female; Humans; Infant; Iodine Radioisotopes; Iodobenzenes; Lymphatic Metastasis; Male; Neoplasm Metastasis; Neuroblastoma; Predictive Value of Tests; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Tomography, Emission-Computed | 1996 |
Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line; Cisplatin; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Female; Humans; Irinotecan; Mice; Mice, Nude; Neuroblastoma; Neuroectodermal Tumors, Primitive; Neuroectodermal Tumors, Primitive, Peripheral; Paclitaxel; Thiotepa; Topoisomerase I Inhibitors; Transplantation, Heterologous | 1996 |
A study of thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Etoposide; Female; Humans; Infant; Male; Neuroblastoma; Prognosis; Survival Rate; Thiotepa; Transplantation Conditioning; Whole-Body Irradiation | 1996 |
N-myc amplification and its relationship to experimental therapy.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Drug Resistance, Neoplasm; Etoposide; Gene Amplification; Genes, myc; Genetic Therapy; Humans; Neuroblastoma; Sensitivity and Specificity; Tumor Cells, Cultured | 1997 |
N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cause of Death; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Gene Amplification; Genes, myc; Genetic Markers; Humans; Infant; Infant, Newborn; Male; Neuroblastoma; Postoperative Complications; Prognosis; Prospective Studies; Survival Rate; Treatment Outcome; Vincristine | 1997 |
Analysis of poly(ADP-ribose) glycohydrolase activity in nuclear extracts from mammalian cells.
Topics: Adenosine Diphosphate Ribose; Animals; Autoradiography; Cell Nucleus; CHO Cells; Chromatography, Thin Layer; Cricetinae; Ethacridine; Etoposide; Glycoside Hydrolases; HeLa Cells; HL-60 Cells; Humans; Kinetics; NAD; Neuroblastoma; Phosphorus Radioisotopes; Tumor Cells, Cultured | 1997 |
[Purging of hemopoietic progenitor cells in autologous transplantation].
Topics: Adult; Bone Marrow Purging; Child; Cyclophosphamide; Deferoxamine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Methylprednisolone; Neuroblastoma; Transplantation, Autologous | 1997 |
The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells.
Topics: Antineoplastic Agents; Apoptosis; Cisplatin; Cyclosporine; Cysteine Endopeptidases; DNA Fragmentation; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Activation; Etoposide; Fas Ligand Protein; fas Receptor; Humans; Immunoglobulin Fragments; Immunosuppressive Agents; Membrane Glycoproteins; Neuroblastoma; RNA, Messenger; Tumor Cells, Cultured; Up-Regulation | 1997 |
N18-RE-105 cells: differentiation and activation of p53 in response to glutamate and adriamycin is blocked by SV40 large T antigen tsA58.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antigens, Polyomavirus Transforming; Antiporters; Apoptosis; Cell Differentiation; Cystine; Doxorubicin; Etoposide; Excitatory Amino Acid Agonists; Glutamic Acid; Homocysteine; Hybrid Cells; Mice; Neurites; Neuroblastoma; Neurons; Neurotoxins; Rats; Rats, Inbred F344; Retina; Temperature; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1998 |
Persistent human cytomegalovirus infection induces drug resistance and alteration of programmed cell death in human neuroblastoma cells.
Topics: Antigens, Viral; Antineoplastic Agents; Antiviral Agents; Apoptosis; Blotting, Western; Cell Division; Cisplatin; Cytomegalovirus; DNA, Viral; Drug Resistance, Neoplasm; Etoposide; Ganciclovir; Genes, Viral; Humans; Neuroblastoma; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Virus Replication | 1998 |
Drug resistance in human neuroblastoma cell lines correlates with clinical therapy.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Humans; Melphalan; Neuroblastoma; Tumor Cells, Cultured | 1997 |
Multidrug resistance modulation in rhabdomyosarcoma and neuroblastoma cell lines.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Small Cell; Cell Survival; Cisplatin; Cyclophosphamide; Cyclosporine; Doxorubicin; Drug Resistance, Multiple; Etoposide; Humans; Kinetics; Lung Neoplasms; Methotrexate; Neuroblastoma; Rhabdomyosarcoma; Time Factors; Tumor Cells, Cultured; Verapamil; Vincristine | 1998 |
Distinct mode of apoptosis induced by genotoxic agent etoposide and serum withdrawal in neuroblastoma cells.
Topics: Animals; Apoptosis; Cell Death; Cerebellum; Culture Media, Conditioned; Culture Media, Serum-Free; DNA Fragmentation; Etoposide; Mice; Mutagens; Neuroblastoma; Transcription Factors; Tumor Cells, Cultured | 1998 |
NGF induces apoptosis in a human neuroblastoma cell line expressing the neurotrophin receptor p75NTR.
Topics: Alzheimer Disease; Animals; Apoptosis; Blotting, Western; Brain-Derived Neurotrophic Factor; Calcium-Calmodulin-Dependent Protein Kinases; Ceramides; DNA Fragmentation; Etoposide; Humans; JNK Mitogen-Activated Protein Kinases; Mitogen-Activated Protein Kinases; Nerve Growth Factors; Neuroblastoma; Neurons; Neurotrophin 3; NF-kappa B; Phosphorylation; Proto-Oncogene Proteins; Rats; Receptor Protein-Tyrosine Kinases; Receptor, Nerve Growth Factor; Receptor, trkA; Receptors, Nerve Growth Factor; Recombinant Proteins; Sphingomyelin Phosphodiesterase; Transcription Factor RelA; Tumor Cells, Cultured | 1998 |
Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Cisplatin; Disease Progression; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Gene Amplification; Genes, myc; Humans; Kinetics; Neuroblastoma; Phenotype; Polymerase Chain Reaction; Time Factors; Tumor Cells, Cultured | 1998 |
Retinoic acid confers resistance to p53-dependent apoptosis in SH-SY5Y neuroblastoma cells by modulating nuclear import of p53.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Apoptosis; DNA Fragmentation; Drug Resistance; Etoposide; Fluorescent Antibody Technique; Gamma Rays; Humans; Neuroblastoma; Nuclear Proteins; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Tretinoin; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1999 |
Distinct mechanisms underlay DNA disintegration during apoptosis induced by genotoxic and nongenotoxic agents in neuroblastoma cells.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 3; Caspases; Cytarabine; DNA; DNA Fragmentation; Etoposide; Mice; Neuroblastoma; Okadaic Acid; Tumor Cells, Cultured | 1999 |
Long-term survivors of advanced neuroblastoma with MYCN amplification: A report of 19 patients surviving disease-free for more than 66 months.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cisplatin; Cyclophosphamide; Disease-Free Survival; DNA, Neoplasm; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Infant; Male; Neuroblastoma; Prognosis; Proto-Oncogene Mas; Proto-Oncogene Proteins c-myc; Survivors; Vincristine | 1999 |
Growth in children with poor-risk neuroblastoma after regimens with or without total body irradiation in preparation for autologous bone marrow transplantation.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Body Height; Bone Marrow Transplantation; Brain Neoplasms; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Etoposide; Growth; Human Growth Hormone; Humans; Infant; Melphalan; Neuroblastoma; Retrospective Studies; Risk Factors; Thyroxine; Transplantation, Autologous; Whole-Body Irradiation | 1999 |
Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines.
Topics: Antineoplastic Agents; Camptothecin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Neuroblastoma; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured | 2000 |
Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Blotting, Southern; Chromosomes, Human, Pair 11; Cisplatin; Cyclophosphamide; DNA-Binding Proteins; Doxorubicin; Etoposide; Exons; Fatal Outcome; Histone-Lysine N-Methyltransferase; Humans; Leukemia, Myeloid; Male; Molecular Sequence Data; Myeloid-Lymphoid Leukemia Protein; Nerve Tissue Proteins; Neuroblastoma; Polymerase Chain Reaction; Proto-Oncogenes; Time Factors; Topoisomerase II Inhibitors; Transcription Factors; Translocation, Genetic; Vincristine | 2000 |
1-phenyl-2-decanoylamino-3-morpholino-1-propanol chemosensitizes neuroblastoma cells for taxol and vincristine.
Topics: Animals; Antineoplastic Agents; Cell Survival; Ceramides; Cyclosporins; Drug Synergism; Enzyme Inhibitors; Etoposide; Glucosyltransferases; Morpholines; Neuroblastoma; Paclitaxel; Tumor Cells, Cultured; Vincristine | 2000 |
Metaiodobenzylguanidine assessment of metastatic neuroblastoma: observer dependency and chemosensitivity evaluation. The SFOP Group.
Topics: 3-Iodobenzylguanidine; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Cisplatin; Cyclophosphamide; Etoposide; Forecasting; Humans; Infant; Multicenter Studies as Topic; Neuroblastoma; Observer Variation; Predictive Value of Tests; Prognosis; Radionuclide Imaging; Radiopharmaceuticals; Remission Induction; Reproducibility of Results; Retrospective Studies; Statistics as Topic; Treatment Outcome | 2000 |
Poly (ADP-ribose) polymerase induction is an early signal of apoptosis in human neuroblastoma.
Topics: Apoptosis; Biomarkers; Caspase 3; Caspases; Cell Survival; Chromatin; DNA Polymerase I; Enzyme Induction; Enzyme Inhibitors; Etoposide; Humans; Kinetics; L-Lactate Dehydrogenase; Neuroblastoma; Poly(ADP-ribose) Polymerases; Staurosporine; Tumor Cells, Cultured | 2000 |
Protective effect of L-deprenyl against apoptosis induced by okadaic acid in cultured neuronal cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cerebellum; Drug Interactions; Enzyme Inhibitors; Etoposide; Hippocampus; Mice; Neuroblastoma; Neurons; Okadaic Acid; Protective Agents; Rats; Rats, Wistar; Selegiline; Tumor Cells, Cultured | 2000 |
Synergistic induction of apoptosis of neuroblastoma by fenretinide or CD437 in combination with chemotherapeutic drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Fenretinide; Flow Cytometry; Free Radicals; Humans; Neuroblastoma; Retinoids; Time Factors; Tretinoin; Tumor Cells, Cultured | 2000 |
MDM2 mediated nuclear exclusion of p53 attenuates etoposide-induced apoptosis in neuroblastoma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Nucleus; DNA Damage; Etoposide; Gene Silencing; Humans; Neuroblastoma; Nuclear Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Subcellular Fractions; Transcriptional Activation; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |
Ubiquitin-binding protein p62 expression is induced during apoptosis and proteasomal inhibition in neuronal cells.
Topics: Animals; Apoptosis; Carrier Proteins; Cells, Cultured; Culture Media, Serum-Free; Cysteine Endopeptidases; Etoposide; Gene Expression Regulation; Hippocampus; Hydroxamic Acids; Immediate-Early Proteins; Mice; Multienzyme Complexes; Neuroblastoma; Neurons; Okadaic Acid; Proteasome Endopeptidase Complex; Rats; RNA, Messenger; Transcription Factor TFIIH; Transcription Factors; Transcription, Genetic; Tumor Cells, Cultured | 2001 |
In vivo activity in a catalytic antibody-prodrug system: Antibody catalyzed etoposide prodrug activation for selective chemotherapy.
Topics: Animals; Antibodies, Catalytic; Biotransformation; Catalysis; Cell Division; Etoposide; Fructose-Bisphosphate Aldolase; Kinetics; Mice; Molecular Structure; Neuroblastoma; Prodrugs; Time Factors; Tumor Cells, Cultured | 2001 |
Differential responses of human neuroblastoma and glioblastoma to apoptosis.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Membrane; Cell Survival; Cytosol; DNA Fragmentation; Enzyme Inhibitors; Etoposide; Glioblastoma; Humans; L-Lactate Dehydrogenase; Neuroblastoma; Poly(ADP-ribose) Polymerases; Protein Kinase C; Staurosporine; Tumor Cells, Cultured | 2001 |
Etoposide toxicity on human neuroblastoma cells in vitro is enhanced by preceeding hyperthermia.
Topics: Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Etoposide; Hot Temperature; Humans; Hyperthermia, Induced; Neuroblastoma; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2001 |
Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Examination; Bone Marrow Transplantation; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Life Tables; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Staging; Neoplasm, Residual; Neuroblastoma; Prognosis; Retroperitoneal Neoplasms; RNA, Messenger; RNA, Neoplasm; Survival Analysis; Treatment Outcome; Tyrosine 3-Monooxygenase; Vincristine | 2001 |
Localised and unresectable neuroblastoma in infants: excellent outcome with primary chemotherapy. Neuroblastoma Study Group, Société Française d'Oncologie Pédiatrique.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Gene Amplification; Genes, myc; Humans; Infant; Infant, Newborn; Life Tables; Male; Neoplasm Staging; Neuroblastoma; Postoperative Complications; Radiotherapy, Adjuvant; Remission Induction; Survival Analysis; Survival Rate; Treatment Outcome; Vincristine | 2001 |
Two secondary leukemias among 15 children given oral etoposide.
Topics: Child; Etoposide; Humans; Leukemia, Monocytic, Acute; Leukemia, Promyelocytic, Acute; Neoplasms, Second Primary; Neuroblastoma | 2001 |
Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines.
Topics: Antineoplastic Agents; Carboplatin; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Drug Resistance, Multiple; Etoposide; Gene Amplification; Humans; Melphalan; Mutation; Neuroblastoma; Nuclear Proteins; Oncogene Proteins, Viral; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Repressor Proteins; Transcriptional Activation; Transduction, Genetic; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |
Neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Doxorubicin; Etoposide; Female; Humans; Infant; Male; Neoplasm Staging; Neuroblastoma; Retrospective Studies; Second-Look Surgery; Survival Rate; Treatment Outcome; Vincristine | 2001 |
Ex vivo pediatric brain tumors express Fas (CD95) and FasL (CD95L) and are resistant to apoptosis induction.
Topics: Adolescent; Animals; Antineoplastic Agents; Apoptosis; Astrocytoma; Brain Neoplasms; Cell Survival; Child; Child, Preschool; Colorimetry; Culture Media, Conditioned; DNA, Complementary; Drug Resistance, Neoplasm; Etoposide; Fas Ligand Protein; fas Receptor; Female; Ganglioglioma; Germinoma; Glioblastoma; Humans; Infant; Jurkat Cells; Male; Medulloblastoma; Membrane Glycoproteins; Mice; Neoplasm Proteins; Neuroblastoma; Neuroectodermal Tumors, Primitive; Pineal Gland; Pinealoma; Recombinant Fusion Proteins; Transfection; Tumor Cells, Cultured | 2001 |
Role of palmitoyl-protein thioesterase in cell death: implications for infantile neuronal ceroid lipofuscinosis.
Topics: Antibiotics, Antineoplastic; Apoptosis; Chromones; Daunorubicin; Enzyme Inhibitors; Etoposide; Humans; Infant; Morpholines; Nerve Degeneration; Neuroblastoma; Neuronal Ceroid-Lipofuscinoses; Neurons; Nucleic Acid Synthesis Inhibitors; Sphingosine; Staurosporine; Thiolester Hydrolases; Transfection; Tumor Cells, Cultured | 2001 |
Oral etoposide following combination chemotherapy and radiation therapy in a patient with advanced adult neuroblastoma led to long survival.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Male; Neuroblastoma; Retroperitoneal Neoplasms; Salvage Therapy | 2001 |
The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Cell Cycle; Chromosomal Proteins, Non-Histone; Cysteine Proteinase Inhibitors; Etoposide; Gene Expression; Humans; Inhibitor of Apoptosis Proteins; Kidney Neoplasms; Membrane Glycoproteins; Microtubule-Associated Proteins; Neoplasm Proteins; Neuroblastoma; RNA, Messenger; Survivin; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2001 |
Immature teratoma of the ovary on fluid cytology.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Biomarkers, Tumor; Bleomycin; Child; Cisplatin; Cytodiagnosis; Diagnosis, Differential; Etoposide; Female; Humans; Immunoenzyme Techniques; Lymphoma, Non-Hodgkin; Neuroblastoma; Ovarian Neoplasms; Rhabdomyosarcoma, Embryonal; Sarcoma, Ewing; Teratoma; Wilms Tumor | 2001 |
Improved survival of children with advanced neuroblastoma treated by intensified therapy including myeloablative chemotherapy with stem cell transplantation: a retrospective analysis from the Tohoku Neuroblastoma Study Group.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Doxorubicin; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Infant; Japan; Melphalan; Myeloablative Agonists; Neuroblastoma; Retrospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Treatment Outcome; Universities | 2001 |
In vitro and in vivo downregulation of MRP1 by antisense oligonucleotides: a potential role in neuroblastoma therapy.
Topics: Animals; Apoptosis; Down-Regulation; Drug Resistance, Neoplasm; Etoposide; Mice; Mice, SCID; Multidrug Resistance-Associated Proteins; Neoplasm Transplantation; Neuroblastoma; Oligonucleotides, Antisense; Prognosis; Transplantation, Heterologous; Tumor Cells, Cultured | 2002 |
Schedule-dependent response of neuroblastoma cell lines to combinations of etoposide and cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cisplatin; Drug Synergism; Etoposide; Humans; Neuroblastoma; Time Factors; Tumor Cells, Cultured | 2002 |
Expression of different mutant p53 transgenes in neuroblastoma cells leads to different cellular responses to genotoxic agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Survival; Cisplatin; DNA Damage; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Etoposide; Gene Expression Regulation; Genes, p53; Humans; Mutation; Neuroblastoma; Radiation Tolerance; Transgenes; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
Cisplatin therapy in infants: short and long-term morbidity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chlorambucil; Cisplatin; Electrolytes; Etoposide; Female; Glomerular Filtration Rate; Humans; Infant; Infant, Newborn; Liver Neoplasms; Male; Morbidity; Neuroblastoma; Prednisolone; Seizures; Teratoma; Time Factors; Vincristine | 1992 |
High-dose rapid schedule chemotherapy for disseminated neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Cyclophosphamide; Drug Administration Schedule; Etoposide; Glomerular Filtration Rate; Humans; Neuroblastoma; Neutrophils; Platelet Count; Vincristine | 1992 |
Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECaT): a new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Chelation Therapy; Child; Child, Preschool; Cyclophosphamide; Deferoxamine; Etoposide; Humans; Infant; Neuroblastoma; Pilot Projects; Remission Induction; Thiotepa | 1992 |
Treatment of advanced neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Infant; Melphalan; Neuroblastoma; Survival Rate; Vincristine | 1992 |
Toxicity of single-day high-dose vincristine, melphalan, etoposide and carboplatin consolidation with autologous bone marrow rescue in advanced neuroblastoma.
Topics: Adolescent; Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Humans; Infant; Kidney; Melphalan; Neuroblastoma; Transplantation, Autologous; Vincristine | 1992 |
Pilot study of high-dose vincristine, etoposide, carboplatin and melphalan with autologous bone marrow rescue in advanced neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Gastrointestinal Diseases; Humans; Infant; Male; Melphalan; Neuroblastoma; Pilot Projects; Transplantation, Autologous; Vincristine | 1992 |
Single institution experience with high-dose cyclophosphamide, continuous infusion vincristine, escalating doses of VP-16-213, and total body irradiation with unpurged bone marrow rescue in children with neuroblastoma.
Topics: Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Dermatitis, Exfoliative; Diarrhea; Etoposide; Female; Humans; Infant; Male; Neuroblastoma; Stomatitis; Thrombocytopenia; Vincristine | 1992 |
Combination chemotherapy with ifosfamide and etoposide is effective in the treatment of central nervous system metastasis of childhood neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Etoposide; Female; Humans; Ifosfamide; Infant; Neuroblastoma | 1992 |
Treatment for stage III-IV neuroblastoma patients: initial response to chemotherapy evaluated by biochemical parameters.
Topics: Abdominal Neoplasms; Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Homovanillic Acid; Humans; Infant; Male; Mediastinal Neoplasms; Neuroblastoma; Vanilmandelic Acid; Vincristine | 1991 |
Chemoimmunotherapy in conjunction with surgery: strategies for management of murine neuroblastoma.
Topics: Animals; Chemotherapy, Adjuvant; Combined Modality Therapy; Etoposide; Female; Liver Neoplasms; Mice; Mice, Inbred Strains; Neoplasm Recurrence, Local; Neuroblastoma; Recombinant Proteins; Tumor Necrosis Factor-alpha | 1991 |
Myeloablative combination chemotherapy without total body irradiation for neuroblastoma.
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Infant; Male; Melphalan; Neuroblastoma; Pelvic Neoplasms; Radiotherapy Dosage; Retroperitoneal Neoplasms; Survival Rate; Thiotepa; Whole-Body Irradiation | 1991 |
[In vivo assessment on the therapeutic effects of etoposide, vincristine and mitomycin C against human neuroblastoma].
Topics: Animals; Child, Preschool; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Infant; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitomycin; Mitomycins; Neoplasm Transplantation; Neuroblastoma; Vincristine | 1991 |
Aggressive surgery combined with intensive chemotherapy improves survival in poor-risk neuroblastoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Infant; Male; Neuroblastoma; Survival Rate | 1991 |
High-dose carboplatin with etoposide (JET regimen) in children with advanced neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child, Preschool; Etoposide; Humans; Neoplasm Staging; Neuroblastoma | 1991 |
Autografting with bone marrow exposed to multiple courses of very high dose cyclophosphamide in vivo and to 4-hydroperoxycyclophosphamide in vitro.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Bone Marrow; Bone Marrow Transplantation; Child, Preschool; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Hematopoiesis; Humans; Infant; Melphalan; Neuroblastoma; Neutrophils; Thiotepa; Vincristine | 1990 |
[Relapsed stage I neuroblastoma successfully treated by allogeneic bone marrow transplantation in second remission: case report of a 7-year-old girl].
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bone Neoplasms; Child; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Melphalan; Neuroblastoma; Remission Induction; Whole-Body Irradiation | 1990 |
Short duration, high dose, alternating chemotherapy in metastatic neuroblastoma. (ENSG 3C induction regimen). The European Neuroblastoma Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Infant; Male; Neuroblastoma; Vincristine | 1990 |
Dose-intensive use of cyclophosphamide in ablation of neuroblastoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Child; Child, Preschool; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Infant; Male; Neuroblastoma; Remission Induction; Vincristine | 1990 |
Advanced neuroblastoma: results of two treatment programs including sequential hemibody irradiation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Infant; Male; Neuroblastoma; Prognosis; Retroperitoneal Neoplasms; Vincristine; Whole-Body Irradiation | 1989 |
Etoposide (VP-16) uptake by tumour spheroids and activity in the presence of Brij 30, formulation additives and sodium salicylate.
Topics: Adjuvants, Pharmaceutic; Animals; Etoposide; Mice; Mitosis; Neuroblastoma; Polidocanol; Polyethylene Glycols; Sodium Salicylate; Surface-Active Agents; Tumor Cells, Cultured | 1989 |
Phase II studies of combinations of drugs with high dose carboplatin in neuroblastoma (800 mg/m2 to 1 g 250/m2): a report from the LMCE group.
Topics: Carboplatin; Carmustine; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Therapy, Combination; Etoposide; Humans; Methoxyhydroxyphenylglycol; Neuroblastoma; Organoplatinum Compounds | 1988 |
Improved prognosis for children with stage IV neuroblastoma: high-dose melphalan and autologous unpurged marrow transplantation after aggressive surgery and short chemotherapy with cisplatinum and etoposide.
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Infant; Male; Melphalan; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroblastoma; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Transplantation, Autologous; Tumor Lysis Syndrome | 1988 |
Repeated high-dose chemotherapy followed by purged autologous bone marrow transplantation as consolidation therapy in metastatic neuroblastoma.
Topics: Abdominal Neoplasms; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Gastrointestinal Diseases; Humans; Infant; Infections; Melphalan; Neuroblastoma; Teniposide; Thoracic Neoplasms; Transplantation, Autologous; Vincristine | 1987 |
Very-high-dose cisplatin and etoposide in children with untreated advanced neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Etoposide; Hearing Loss; Humans; Infant; Neuroblastoma; Neutropenia; Pilot Projects; Water-Electrolyte Imbalance | 1988 |